East Tennessee State University

Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations

Student Works

May 1997

Characterization of Angiotensin Ii Receptor
Subtypes in the Brain
David L. Saylor
East Tennessee State University

Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Neurology Commons
Recommended Citation
Saylor, David L., "Characterization of Angiotensin Ii Receptor Subtypes in the Brain" (1997). Electronic Theses and Dissertations. Paper
2973. https://dc.etsu.edu/etd/2973

This Dissertation - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State
University. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East
Tennessee State University. For more information, please contact digilib@etsu.edu.

INFORMATION TO USERS

This manuscript has been reproduced from the microfilm master. UMI
films the text directly from the original or copy submitted. Thus, some
thesis and dissertation copies are in typewriter face, while others may be
from any type o f computer printer.
The quality of this reproduction is dependent upon the quality of the
copy submitted. Broken or indistinct print, colored or poor quality
illustrations and photographs, print bleedthrough, substandard margins,
and improper alignment can adversely afreet reproduction.
In the unlikely event that the author did not send UMI a complete
manuscript and there are missing pages, these will be noted. Also, if
unauthorized copyright material had to be removed, a note will indicate
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by
sectioning the original, beginning at the upper left-hand comer and
continuing from left to right in equal sections with small overlaps. Each
original is also photographed in one exposure and is included in reduced
form at the back of the book.
Photographs included in the original manuscript have been reproduced
xerographically in this copy. Higher quality 6” x 9” black and white
photographic prints are available for any photographs or illustrations
appearing in this copy for an additional charge. Contact UMI directly to
order.

UMI
A Bell & Howell Information Company
300 North Zed) Road, Ann Axbor MI 48106-1346 USA
313/761-4700 800/521-0600

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHARACTERIZATION O F A NG IO TENSIN II
RECEPTOR SUBTYPES IN TH E BRAIN

A Dissertation
Presented to
the Faculty of the Department of Physiology
James H. Quillen College of Medicine
East Tennessee State University

In partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy

By
David Saylor
May 1997

R eproduced with permission of the copyright owner. Further reproduction prohibited w ithout permission.

UMI Number: 9726821

UMI Microform 9726821
Copyright 1997, by UMI Company. All rights reserved.
This microform edition is protected against unauthorized
copying under Title 17, United States Code.

UM
I

300 North Zeeb Road
Ann Arbor, MI 48103

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPROVAL

This is to certify that the Graduate Committee of
David Saylor
met on the
4th day of December, 1996.
The committee read and examined his dissertation, supervised his
defense of it in an oral examination, and decided to recommend that his study be
submitted to the Graduate Council, in partial fulfillment of the requirements for
the degree of Doctor of Philosophy in Biomedical Science.

Chair, Graduate Committee

Signed on behalf of
The Graduate Council
Interim Dean, School of Graduate
Studies
ii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ABSTRACT

C HA R AC TER IZATIO N O F A N G IO TE N S IN II

R E C EP TO R SU BTYPES IN T H E BRAIN

by
David Saylor
The present studies explore binding, distribution, and function of angiotensin II
(All) receptors (ATi and AT 2 ) in the brain.
The discovery that sulfhydryl reducing agents masked some but not all All
receptors in the brain prompts an evaluation of commonly used binding assay
buffer constituents. EDTA enhances binding (40%) at both AT^ and AT2 nuclei,
while bacitracin did not alter binding at either receptor subtype. Phenanthroline
and BSA differentially altered binding at A ^ (220% of control) and AT2 (118% of
control) receptors. The results indicate that phenanthroline and BSA would be
poor buffer constituents for studies comparing binding at A Ti and AT2 receptors.
All receptors were mapped in normotensive and genetically hypertensive
hamster brains and the subtype composition estimated for a number of brain
nuclei and the pituitary. Binding in the hamster was similar to that previously
observed in the rat brain with exceptions: 1) additional binding in the medial
habenula and interpeduncuiar nuclei, 2) absence of binding in the inferior olive,
suprachiasmatic nucleus, medial amygdala, piriform cortex, and subthalamic
nucleus and 3) quantitative differences in the dorsomotor nucleus of the vagus,
striatum, hippocampus and anterior pituitary. Unlike studies of the normotensive
and spontaneously hypertensive rat, we found no significant differences in
binding distribution, density or subtype composition when comparing normal and
genetically hypertensive hamsters.
Finally, the effects of brain angiotensin II (All) on central catecholamine utilization
were determined. W e found no significant differences in norepinephrine,
epinephrine or dopamine utilization in rat brain homogenates following
intracerebroventricular injection of All. Although there is evidence that All alters
catecholamine utilization in some brain nuclei, these alterations appear limited
(anatomically and/or quantitatively) to a relatively small portion of the brain
catecholaminergic system.
iii

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

The results indicate that the selection of buffer constituents is an important
consideration for All binding studies, that there are minor species differences in
the distribution of All receptors in the brain and that despite substantial functional
and anatomical overlap, only a relatively small portion of the brain
catecholaminergic system is modulated by angiotensin II.

iv
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CHAPTER 1
INTRO DUCTIO N

The Renin Angiotensin System
Nearly a century ago, Tigerstedt and Bergman (1898) obtained an extract
from the renal cortex of rabbits that produced a pressor response upon
intravenous injection. They named this substance ‘renin’ and characterized it as
heat sensitive and impermeable to semi-permeable membranes, indicating that
the substance was most likely (as was later confirmed) a protein. Furthermore,
Tigerstedt thought the substance was probably released from the kidney into the
circulation to produce its effects (this has also been confirmed).
Later, Goldblatt, a pathologist, noticed arterio- and arteriolosclerosis in
hypertensive patients at autopsy. Goldblatt suspected that obstruction of blood
flow to the kidney was related to hypertension. In 1934, Goldblatt e ta l.
demonstrated sustained hypertension with renal ischemia using constricting
clamps on the renal arteries of experimental animals. This and additional work by
Goldblatt proved that this type of hypertension was produced by a humoral agent
of renal origin (Goldblatt, 1947; 1948). The subsequent search for the humoral
agent led to the re-discovery of renin.

1
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Later work revealed that renin did not act alone. Page e ta l. (1940) and
Braun-Menendez etal. (1940) independently proposed that renin might act as an
enzyme and named the substrate angiotonin and hypertensin, respectively.
Finally, in 1961, Page and Braun-Mendez agreed to call the new substance
“angiotensin". An early assay for angiotensin in arterial blood samples
demonstrated that this substance was elevated by a factor of about 20 in
malignant hypertensive patients, while only about one-half of the patients with
benign essential hypertension had elevated levels (Kahn e ta l., 1952). This
finding stimulated further study of renin and angiotensin. Attempts at purifying
angiotensin from plasma uncovered two forms - angiotensin I (Al) and
angiotensin II (All), and another enzyme - angiotensin converting enzyme (ACE)
that converted one form into the other (Skeggs et al., 1954; Lentz et al., 1956).
These components collectively form the renin-angiotensin system (RAS)
(depicted in figure 1-1) with All being the primary affecter molecule. All acts on

Angiotensinogen
Renin
Angiotensin I t
(Decapeptide)

Angiotensin li
(Octapeptide)

Figure 1-1. The renin-angiotensin system.
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many tissues to produce a variety of effects. Most of the known actions of All
involve blood pressure regulation, sodium/fluid balance, or growth and
development. Consistent with the array of actions of this peptide, a number of
angiotensin receptor subtypes have been described and localized in a number of
tissues. The profound effect All has on blood pressure has made this system a
primary target for antihypertensive agents, and a wide variety of drugs is
currently available to block renin secretion, renin action, conversion from Al to
All, and All receptors. Each component of this diverse and complex system will
now be discussed individually.

Renin
Preprorenin (45 kD) is produced in the kidney. The human cDNA has
been cloned and sequenced (Parmentier etal., 1982). This precursor is
processed post-translationally into the still inactive prorenin, then finally, into the
active renin. The final processing of prorenin can occur intracellularly, or in the
circulation following secretion (plasma prorenin levels are approximately 10'11 M).
Renin is secreted in two forms. A two chain form is secreted by a regulated
mechanism while a single chain renin (with 6 times the enzymatic activity) is
constitutively secreted (Pratt e ta l., 1983). Interestingly, circulating renin is
apparently complexed to a renin-binding protein that inhibits its action (Inone et
al., 1990). Renin is very specific in function and substrate and does not appear to
belong to any general class of proteases. However, there are some structural
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similarities to the acid proteases pepsin and cathepsin D, which are also capable
of producing angiotensin I (Paiva and Grandino, 1973; Hackenthal etal., 1978).
The renin catalyzed conversion of angiotensinogen to Al is the
physiologically regulated reaction of the RAS with plasma All levels determined
by plasma renin activity. Release of renin is regulated by a host of factors of both
intra and extrarenal origin. Within the kidney, the renal arterial perfusion pressure
and sodium delivery to the macula densa regulate renin release. Additional
regulatory components include the renal nerves, circulating catecholamines, All,
and vasopressin. Additional stimuli, both endogenous and exogenous to the
kidney, may override other factors under certain conditions. Renin release may
be reflexively altered by carotid sinus arterial baroreceptors and/or by vagally
mediated cardiopulmonary receptors. Additionally, psychological stresses are
known to increase renin release. All of these factors are integrated by
juxtaglomerular cells by a not completely understood process that probably
involves a common second messenger system (Zehr etal., 1980; Katz and
Malvin, 1993). Products of the arachidonic acid and cyclooxygenase interaction
and/or prostaglandins may be involved (Katz and Malvin, 1993).

Angiotensinogen
Angiotensinogen, a 55-60kD glycoprotein produced and constitutively
secreted (Deschepper and Reudelhuber, 1990) by the liver, has been isolated
and characterized. Furthermore, cDNA cloning and analysis have provided the
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primary structures of rat (Ohkubo e tal., 1983), human (Kageyama etal., 1984),
and mouse (Clouston etal., 1988) angiotensinogen. This tetradecapeptide differs
at the N-terminus in different species (Tewksbury e ta l., 1981), allowing
polyclonal and monoclonal antibody production and direct immunoassay of the
C-terminal portion (Genain e ta l., 1984).
Angiotensinogen is present in plasma at about 1 |iM and in cerebrospinal
fluid (CSF) (Genain etal., 1984; Ito etal., 1980; Schelling e ta l., 1983). Since the
Km of renin for angiotensinogen is around 1.25 jiM , angiotensinogen is not in vast
excess and alterations in plasma angiotensinogen levels can alter plasma All
levels. However, because changes in plasma angiotensinogen levels occur
slowly (hours or days) this substance does not mediate acute All responses.
Angiotensinogen release is regulated by angiotensin II, glucocorticoids
(especially dexamethasone), estrogens and thyroid hormones (Tewksbury, 1983;
Menard etal., 1983). It is important to note that angiotensin II is a positive
regulator for angiotensinogen (Li and Brasier, 1996), but negatively regulates
renin (Menard eta l., 1983; Hermann and Dzau, 1983). Thus, angiotensin II
inhibits further angiotensin II formation and causes a replenishment of the used
angiotensinogen.
Interestingly, angiotensinogen levels are increased with inflammation
(Nielsen and Knudsen, 1987). All is also elevated and may participate in the
immune response during inflammation (Femandez-Castello e ta l., 1987).
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Angiotensin Converting Enzyme
Skeggs and co-workers (1956) discovered angiotensin converting enzyme
(ACE) while attempting to isolate angiotensin I. In the presence of chlorine a
‘second form’ of angiotensin (missing two amino acids from the C-terminal) was
isolated. Independently, in the early 1960s, kininase II, which cleaves a dipeptide
from bradykinin, was discovered by Yang and Erdos (1967). Yang and co
workers later demonstrated that both reactions were mediated by a single
dipeptidyl decarboxypeptidase (1970). This single enzyme, therefore, inactivates
a hypotensive agent and activates a pressor agent. This enzyme also cleaves
des-Arg9-bradykinin, neurotensin, chemotactic peptide, substance P, luteinizing
hormone releasing hormone, cholecysiokinin-8, [Leu15]gastrinn -1 7 and the opioid
peptides enkephalin, heptapeptide, p-neo-endorphin, and dynorphini-a.
ACE exists in bound and free forms. A membrane-bound form is present
in vascular beds, bound to endothelial cells. The lung, having a large vascular
bed, hosts much of the ACE activity for cleaving circulating peptides including Al
and bradykinin. However, membrane bound ACE is also present in arteries and
veins (endothelial), microvilli, kidney proximal tubules, brush border of placenta,
intestine and choroid plexus (epithelial), subfornical organ, pallidonigral dendrites
and median eminence (neuroepithelial), testis, prostrate and epididymis (male
genital tract). Free ACE is present in blood, urine, lung edema, amniotic fluid,
cerebrospinal fluid, lymph, and seminal plasma. It is not known if the free form is
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secreted or cleaved from the membrane bound C-terminal fragment (Skidgel and
Erdos, 1993).
The involvement of this enzyme in the RAS is in the formation of All from
Al. The cleavage of Al has a Km of approximately 5x1 O'5 M. Since Al is present in
sub nanomolar concentrations, the rate of reaction is proportional to Al
concentration, which is renin dependent. Therefore, this step is not
physiologically regulatory. However, the metal requiring nature of this enzyme
makes it a primary target for intervention. ACE inhibitors form a large and
clinically important class of antihypertensive agents.

Angiotensins
Angiotensin I (Al) (figure 1-2) is formed by the action of renin on
angiotensinogen. This decapeptide serves as substrate for angiotensin

Angiotensin Peptides
A

l

(^ s ^ !(^ ^ ^ (V a l)(^ ^ T )(^ n e ^ X H is )(P ro )(^ h ^ H is )(L e u ^ i

A ll
AIII
AIV
A( 1-7)
Figure 1 - 2 . Amino acid sequences of angiotensin peptides.
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converting enzyme which removes two amino acids from the C-terminal end to
produce the active octapeptide angiotensin II (All).
All is now known to affect multiple targets to produce a co-ordinated
cardiovascular response. All increases heart rate and contractile force, constricts
blood vessel smooth muscle cells, and stimulates the pituitary to secrete
vasopressin, another potent vasoconstrictor (Skeggs, Kahn, and Shumway,
1956). All also regulates sodium and fluid balance by stimulating aldosterone
release from glomerulosa cells of the adrenal cortex (Davis, 1963; Wright and
Harding, 1994). All acts in the kidney to decrease filtration by contracting
glomerular mesangial cells (Fujiwara etal., 1989) and smooth muscle cells in
efferent arterioles (Gassee et al., 1976; Gekle and Silbernagl, 1993) and
excretion by increasing sodium and water re-absorption in the proximal tubule
(Mitchell and Navar, 1991). All stimulates catecholamine release in the brain
(Jenkins etal., 1995), and from the adrenal chromaffin cells (Kimura etal., 1992).
Finally, All acts in the brain to stimulate drinking and sodium appetite as well as
increases sympathetic tone and decreases parasympathetic tone (Wright and
Harding, 1992). All has also been implicated in reproduction (Morris & Paulson,
1994; Phillips etal., 1995), growth and development (Huckle and Earp, 1994;
Wolf, 1995), inflammation (Farber eta l., 1990; Weinstock etal., 1987), right
ventricular hypertrophy in hypertension (W aeberand Bruner, 1996), and
cognition and memory (Wright and Harding, 1994).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

9

Early attempts to antagonize All activity were limited to the disadvantages
of peptidic substitution based antagonists. Often a sarcosine substitution at
position 1 was employed to increase stability. Further substitution at position 8
removes activity and may further stabilize the antagonist. More recently, nonpeptidic receptor antagonists have been developed and demonstrate
heterogeneity in receptor types (Chiu eta l., 1989; Whitebread etal., 1989).
Angiotensin III (Alll) can be produced by aminopeptidase activity on All, or
from Al without All production via aminopeptidase activity and subsequent ACE
action. This peptide retains about 3 0% of the pressor activity of All (Khosla et al.,
1974). However, Alll might play a more significant role in mediating aldosterone
release (Campbell etal., 1974; Mendelsohn and Kachel, 1980) and may be
equipotent or more potent than All in eliciting vasopressin release from the
pituitary (Wright and Harding, 1994). Indeed, in the brain, some of the actions
currently ascribed to All may actually be mediated by Alll or other smaller
peptide fragments formed locally within the tissue (Papouchado etal., 1995;
Unger et al., 1988). In fact, Alll is equipotent or more potent than All in activating
the mas oncogene product. This receptor is structurally similar to angiotensin II
receptors but is not antagonized by either selective antagonist. Furthermore this
gene product is expressed in specific brain regions but is expressed in very low
levels if at all at peripheral sites (Hanley, 1991).
Angiotensin IV (AIV) (amino acids 3-8 of angiotensin II) binds with high
affinity to a unique receptor type but not to other angiotensin receptors.
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Conversely, other angiotensins have very low affinities for the AIV receptor. AIV
and AIV receptors have been localized to discrete brain regions and to a variety
of other tissues (Swanson etai., 1992).
Angiotensin-(1-7) (amino acids 1-7 of angiotensin II) also demonstrates
activity. Schiavone e t a i (1988) indicate that this fragment is equipotent with All
in stimulating vasopressin release. In the brain angiotensin-(1-7) mimics some
but not all All actions (Campagnole-Santos etai., 1990) and appears to be more
potent that All in stimulating prostaglandin synthesis in glioma cells (Jaiswal et
al., 1991). However, it is unlikely that this fragment acts via All receptors (Rowe
etai., 1995).
Angiotensin peptides are degraded through a variety of non-specific
amino, carboxy, and endopeptidases. Additional fragmentation products are
thought to be inactive.

Angiotensin Receptors
The search for non-peptidic receptor antagonists led to the discovery of
angiotensin II receptor subtypes in 1989. The antagonist losartan demonstrates
selectivity for the A ^ receptor while PD 123177 demonstrates AT 2 selectivity
(Chiu e ta i., 1989; Whitebread e ta i., 1989). These receptor subtypes are also
differentially sensitive to sulhydryl reducing agents. All receptors have been
localized and characterized in a variety of tissues including vascular smooth
muscle, adrenal cortex, kidney, myocardium, brain, adrenal medulla, liver, uterus,
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pituitary, gut, and gonads (Catt, 1993). The known actions of All are mediated by
the ATi receptor and are antagonized by losartan but not by PD123177.
Both ATi and AT 2 receptors have now been cloned and sequenced
(Murphy etai., 1991; Sasaki e ta i., 1991; Nahmias and Strosberg, 1995). A ^
receptors have been subdivided into A T1a and A T ^ receptors based on
sequence heterogeneity. However, there appears to be little if any functional
difference between the ATi types. All three receptor types contain 7 membrane
spanning regions and meet the structural requirements for G-protein linkage. ATi
receptor are known to act through the G-proteins Gq and Gj and couple to
phospholipases C, D2, and A2l adenylate cyclase, and calcium channels (Catt,
1993). Down regulation by All appears to be the most significant factor regulating
A ^ expression (Lassegue e ta i., 1994). There is some evidence that AT2
receptors link to Gj proteins to modulate K+ channels in primary neuronal cultures
and AT2 expression may be regulated by growth-related factors (Kang e ta i.,
1994).
Evidence suggests further heterogeneity in both ATi and AT2 receptors.
Initially, AT2 receptors were thought to be not coupled to guanidine nucleotides
because of observed insensitivities to GTPyS (Nahnias and Strosberg, 1995).
Furthermore, some, but perhaps not all, AT2 receptors demonstrate enhanced
binding in the presence of sulfhydryl reducing agents. There is also some
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evidence for a unique ATi receptor in renal mesangial cells but cloning and
sequencing will be necessary for confirmation (Lassegue e t a i , 1994).

Multiple Local Tissue RAS
There may actually be several independent renin angiotensin systems
operating locally within certain organs. Various components of the RAS have
been described in the brain, anterior pituitary, testes, ovaries, adrenal cortex,
kidneys, heart, blood vessel walls, and brown and white fat (Ganong, 1994).
However, many of these localizations employ very sensitive molecular methods
and use polymerase chain reaction (PCR) amplification (Dostal e t a i, 1992;
Ganong, 1994). The degree of expression may not be physiologically significant
and could, in some cases, represent incomplete inhibition. All (and/or another
active angiotensin fragment) probably has paracrine and/or autocrine functions in
at least some of these tissues and probably acts as a neurotransmitter in the
brain (Ganong, 1994). These functions may or may not interact with the
hormonal RAS. However, there is some evidence that plasma renin activity alone
may not account completely for plasma All levels, suggesting a contribution by at
least some local systems (Unger e t a i, 1991).

The RAS in the Brain
The evidence for an independent local angiotensin system is most
compelling in the brain. Sulfhydryl reducing agents such as dithiothreitol and
mercaptoethanol have been found to differentially affect binding with respect to
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angiotensin II receptor subtypes in the brain (Rowe e ta i. 1990a; Speth etai.,
1990). Significantly, a number of previously unreported binding sites were
observed (Rowe et a i, 1990b) in the absence of sulfhydryl reducing agents,
which were routinely included in angiotensin II binding assays in the brain prior to
this discovery. Interestingly, many brain nuclei demonstrating binding are not
known to be involved in cardiovascular or dipsogenic activity, suggesting that
angiotensin II may have additional functionality in the brain. Additionally, most of
the angiotensin II receptor populations in the brain are not accessible from the
circumventricular organs, suggesting that a source of angiotensin II exists within
the brain.
All of the components of the renin angiotensin system have now been
localized in the brain (Moffet e tai., 1987; Phillips e ta i., 1993). Angiotensinogen,
angiotensin II, and angiotensin II receptors have been localized within the brain
by in situmRNA hybridization (Fuxe e ta i., 1988), immunocytochemistry (Lind et
a i, 1985), and receptor autoradiography (Gehlert e t a i, 1986; Mendelsohn e t a i,
1984) respectively, and demonstrate good anatomical correspondence in many
brain areas (Bunnemann e t a i, 1991).
Despite generally low levels in the brain, renin has been localized in
neurons and nerve terminals and may also be present in glial cells (Fuxe et a i,
1980; Fischer-Ferraro e t a i, 1971; Samani e t a i, 1988; Yang and Neff, 1972).
Most of the angiotensin converting enzyme in the brain is located in the choroid
plexus and circumventricular organs with some on neuronal membranes
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(Ganong, 1993). However, there are other enzymes present in the brain (like
tonin and cathepsin G) that are capable of generating angiotensin II from
angiotensin I or directly from angiotensinogen (Boucher e t a i, 1974; Tonnesen
e ta i. 1982).
Angiotensinogen messenger RNA (mRNA) has been localized to
astrocytes, while angiotensinogen immunoreactivity has also been found in
neurons. This suggests that angiotensinogen is produced only in astrocytes but
is then taken up by neurons for conversion to angiotensin II. Angiotensinogen
(mRNA and/or immunoreactivity), angiotensin II, and angiotensin II receptors
have been localized to the subfornical organ, area postrema, median eminence,
spinal trigeminal nucleus, inferior olivary nucleus, dorsal motor nucleus of the
vagus, nucleus tractus solitarius, locus coeruleus, regions of the central grey,
ventral nuclear complex, reuniens nucleus, mammillary nucleus, ventromedial
and dorsomedial nuclei, suprachiasmatic nucleus, paraventricular and
periventricular nuclei, supraoptic nucleus, medial preoptic area, median preoptic
nucleus, and lateral septum.
However, angiotensinogen and angiotensin II are found in a few areas
where angiotensin II receptors have not been reported. These areas include
pontine central grey, the substantia nigra, the zona incerta, thalamic
paraventricular nucleus, arcuate nucleus, the lateral preoptic area, medial septal
nucleus, nuclei of the band of Broca, bed nucleus of the stria terminalis, and the
central amygdaloid nucleus (Bunneman etai., 1991).
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Summary and Discussion
The kidney was linked to cardiovascular function in classical experiments
by Tigerstedt and Bergman (1898). Additional work revealed a hormone system
involving angiotensinogen from the liver, renin from the kidney and a converting
enzyme from endothelial cells. The primary affector peptide, angiotensin II, acts
on receptors present in a number of peripheral tissues and the brain to co
ordinate complex cardiovascular and fluid/salt balance responses.
Recent discoveries indicate that the renin-angiotensin system may also
have paracrine/autocrine functions. Evidence is mounting for the existence of
local RAS within a variety of tissues/organ systems. The most convincing
evidence exists in the brain, where angiotensin II appears to act as a
neurotransmitter. All of the components of the RAS have been found in the brain
as well as alternative synthesis pathways capable of forming angiotensin II.
Despite the generally good co-localization of components of the renin
angiotensin system within the brain, a few mismatches remain. Bunnemann et
ai. (1991) describe three major types of mismatches occurring in the brain renin
angiotensin system:

1

) The presence of angiotensinogen mRNA,

angiotensinogen immunoreactivity, All receptors, and the lack of angiotensin
converting enzyme and/or All in distinct areas; 2) Angiotensinogen m RNA and
immunoreactivity in association with moderate to low levels of converting
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enzyme, but All and All receptors are not detectable and 3) The lack of
detectable binding sites for All with the presence of all the other components of
the RAS. The first discrepancy may be due to a relatively short half life of
angiotensin II making detection of low levels difficult. With respect to the second
type of discrepancy, angiotensinogen m RNA appears only in astrocytes
(Bunnemann etai., 1992; Stornetta e ta i., 1988) whiie angiotensinogen-like
immunoreactivity has also been visualized in some neurons (Intebi etai., 1990;
Thomas and Semia, 1988). Angiotensinogen may be produced by astrocytes and
taken up by neurons at the location of the cell body, packages, transported, and
converted to angiotensin II in transport or in the distant nerve terminal. Therefore,
we might expect angiotensin II and angiotensin II receptors to be localized
differently than angiotensinogen mRNA and immunoreactivity. Concerning the
second type of discrepancy, the co-localization of all necessary components of
the RAS with the exception of angiotensin II receptors, angiotensin II could be
formed in (and present at) cell bodies as well as transported to nerve terminals at
distant sites where All receptors would be localized. However, the possibility
remains that some angiotensin II receptors evade detection in current assays.
The remaining discrepancies with respect to the absence of All receptors where
additional RAS components are present may be indicative of additional
angiotensin II receptor subtypes being masked by in vitro conditions. Previously,
the discovery of angiotensin II receptor subtypes and the subsequent unmasking
of additional All binding in the brain resolved some discrepancies in distributions
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of RAS components in the brain (Rowe etai., 1990b). Further evidence of
additional receptor subtypes comes from recent molecular biology based
experiments that examine angiotensin receptor genes for sequence and
processing heterogeneity.
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CHAPTER 2
SPECIFIC AIM S

The overall objective of the current research is to further characterize AT,
and AT 2 receptors in the central nervous system. Approaches employed to meet
this objective include: 1 ) verification of buffer medium for binding assays;

2

)

evaluation of central AT, and AT 2 receptor distributions in the hamster; and 3)
characterization of the interaction between central angiotensinergic and
catecholaminergic systems. Each of these experiments is described below.

Evaluation of Buffer Constituents
Early binding studies examining angiotensin II receptors employed a
variety of peptidase inhibitors in the binding assay in order to preserve the
labeled angiotensin II ligand. Indeed, early studies indicated that sulfhydryl
reducing agents were necessary (Chen etai., 1982; Printz etai., 1987) to protect
125

l-angiotensin II. This practice presupposes that the buffer constituents do not

affect the binding reaction. However, when amino and carboxy substituted
angiotensin analogues (i.e.

125

l-[Sar1, llea]-Angiotensin II), which are less

susceptible to aminopeptidase and carboxypeptidase activity, were employed in
the absence of sulfhydryl reducing agents, additional angiotensin II binding was
unmasked (Rowe etai., 1990b). Additionally, the differential sensitivity to

18
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sulfhydryl reducing agents corresponds to different angiotensin II receptor
subtypes (Rowe etai., 1990a). This precedent prompts re-evaluation of
commonly used buffer constituents to determine if the procedures used provide a
valid comparison of ATi and AT 2 binding characteristics.
Angiotensin II receptor density is measured by in vitro receptor
autoradiography at a number of brain nuclei known to contain nearly pure
populations of ATi or AT 2 receptors. Receptors are labeled with

125

I-SIAII in the

presence and absence of various commonly used buffer constituents to
determine if an inhibitor preferentially interferes with binding at one or the other
subtype.

Receptor Localization and Subtype Characterization in the Hamster
The ATi and AT 2 receptor distributions are determined in normal and
genetically hypertensive hamster strains. The brain angiotensin system has been
implicated in the hypertension of the spontaneously hypertensive rat, which
demonstrates increased levels of both angiotensin II and angiotensin II receptors
(Weyhenmeyerand Phillips, 1982; Gehlert etai., 1986b; Hwang e ta i., 1986). In
order to determine if this is true of other mammalian species and to attempt to
correlate angiotensin II receptors in the brain with additional physiological
systems, angiotensin II receptor subtypes will be examined in the brains of
normotensive and spontaneously hypertensive hamsters by in vitro receptor
autoradiography.
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The Effects of Angiotensin II on Brain Catecholamine Utilization
Catecholamines have been implicated in a number of central angiotensin
II responses (Fitzsimons and Setler, 1975; Reader e t a i , 1986; Braszko and
Wisniewski, 1990). Additionally, intracerebroventricular (i.c.v.) injection of
norepinephrine or dopamine mimics some of the actions of i.c.v. injection of
angiotensin II. Furthermore, angiotensin II (i.c.v. or microinjection via
microdialysis) has been shown to alter catecholamine utilization in specific brain
regions (Sumners and Phillips, 1983; Dwoskin etai., 1992; Jenkins etai., 1995).
Additional evidence suggests that angiotensin II may act as a
neuromodulator via AT 2 receptors in the locus coeruleus (Xiong and Marshall,
1990,1994). Specifically, angiotensin II inhibited the excitatory stimulation of
glutamate in a specific manner and was sensitive to AT2, but not A ^ selective
antagonists. Therefore, we hypothesize that angiotensin II may act, in part, by
altering catecholamine utilization throughout the central catecholaminergic
system.
To test this hypothesis, groups of 10 conscious, chronically canulated rats
will receive i.c.v. injections of All, artificial C S F (aCSF), All + losartan or All +
PD123177. After decapitation, the brains will be dissected, homogenized, and
assayed for catecholamine utilization by high performance liquid chromatography
(HPLC).
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CHAPTER 3
MATERIALS AND METHODS

In Vitro Receptor Autoradiography
Animals were anesthetized with Nembutal (80 mg/kg), perfused
intracardially with chilled phosphate buffered saline, and the brains were
removed quickly and stored at -20 °C. Whole brains were cryostat sectioned
(20 pm, -15 °C) and thaw mounted onto sets of adjacent gelatin coated slides. In
some instances, one slide from each set was thionin stained to serve as a
histological reference and the other slides were returned to the freezer. Frozen
slides were placed on a warming plate, pre-incubated in buffer at room
temperature for 30 minutes, and transferred to buffer containing

125

l-[sar 1 ,ile8]-AII

(1 2 5 I-SIAII) for one or two hours. The tissues were then rinsed, dried in a stream
of hot air, mounted onto boards along with

20

pm thick 125l standards

(Microscales, Amersham, Arlington Heights, IL) and apposed to film (Kodak SB5)
for 5-6 days. The film was developed with Kodak D-19 developer and

125

I-SIAII

binding was quantified densitometrically using the MCID video based image
analysis system (Imaging Research Systems, Ontario Canada). Binding was
determined as fmoles ligand per gram wet weight of brain tissue and specific

21
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binding was calculated as total

125

I-SIAII binding minus binding in the presence of

All (10' 6 M).

Thionin Staining
At room temperature, slides containing freshly sectioned tissue were
incubated sequentially in thionin staining solution (10 min), water ( 2 dips), 50%
ethanol (2 dips), 70% ethanol (15 seconds), 95% ethanol (1 minute), 100%
ethanol (3 minutes), and xylene (5 minutes). Finally, coverslips were mounted
over the slides.

Development of Autoradiograms
Exposed film (Kodak SB5) was removed from tissue containing cassettes
in the dark using a photographic safe light. Film was developed with agitation for
2 minutes in Kodak D-19 Developer, soaked (30 seconds) in a stop solution (2%
acetic acid) and fixed in Kodak Rapid Fixer (5 minutes). The film was rinsed in
flowing water for

2 0

minutes or until clear and dipped in photoflo before hanging

to dry.

Densitometric Image Analysis
Radioligand binding density was quantitated using an M CID video based
image analysis system. The camera, light source, and lens were adjusted as
desired. The lens aperture was then adjusted to provide a green field to define
the shading error adjustment. The image analysis system was then calibrated for
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linear distance using a reticule. The lens aperture was then adjusted as desired
and a density calibration was performed using the image of the 125l standards on
the autoradiogram to be quantitated.
A 0.15 x 0.15 cm2 sampling box was used to quantitate the highest
observed density (pseudocolor mode) within a given nucleus on an image
corresponding to an individual brain section. For each treatment group, each
brain nucleus for each animal was measured on a number of sections (the exact
number depending upon the anatomical dimension of the nucleus) and an
average taken. When appropriate measurements for a given nucleus were
obtained from both the left and the right sides of the brain.

Analysis of Radioligand Degradation
For each animal, samples were taken from each buffer before and after 60
or

120

minute incubation of brain slices. Samples were frozen and shipped with

dry ice in radioactive packaging to Dr. Robert Speth at Washington State
University where they were analyzed for

125

I-SIAII and radiolabelled fragments by

reverse phase C i 8 (microsorb) HPLC (Rainen Instr., Woburn, MA) with a
radioisotope detector (Beckman Model 171, Beckman Instr., Palo Alto). Peak
areas for 125l labeled compounds were quantitated as height times width at half
the peak height. Several peaks were resolved with 19% acetonitrile, 81%
triethylamine phosphate (TEAP) at pH 3.0. The peak corresponding to

125

I-SIAII

could not be further resolved by extending retention times by using a mobile
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phase with 17% acetonitrile (pH 4.0) or by replacing TEAP with triethylamine
acetate (TEAA).

Intracerebroventricular Injections
Animals were anesthetized with nembutal (70 mg/kg, intraperitoneal) and
surgical anesthesia was maintained with ketamine/acepromasine (intramuscular).
After trimming the top of the head, animals were placed in a stereotaxic frame.
Under sterile conditions, a midline incision was made over the scalp and the skin
deflected. The skull was scraped to remove membranous tissue and positioned
such that the top of the skull was horizontal and flat. Stereotaxic co-ordinates
were taken with a drill placed on the bregma surface feature and the drill co
ordinates were determined to be 0.9 mm posterior and 1 . 6 mm lateral to bregma
on the left side of the animal. Holes were drilled at this site and approximately 1.5
mm anteriorly and posteriorly. Screws were placed in the anterior and posterior
holes. The drill was replaced with the cannula holder and a sterile guide cannula
was placed within the holder. The cannula tip was placed on bregma and the co
ordinates taken. The cannula was placed at co-ordinates 0.9 mm posterior,

1 .6

mm lateral (left side), and 3.0 mm ventral to bregma. The skull was checked for
dryness and any fluid on the skull surface was removed. Cranioplastic cement
(liquid and powder portions) was mixed and applied, under the screw tops,
covering the screws, around the cannula and into the lower threads on the
cannula base. After the cement had hardened (about 20 minutes), the cannula
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was released from the holder, the skin was closed around the cannula with
autoclips and a dummy cannula was screwed into place inside the guide
cannula.
Approximately

1

week following surgery, cannula placement was

confirmed by observation of a drinking response following i.c.v. injection of
angiotensin II (150 picomoles in 3 pi). A syringe (Hamilton, 10 p!) was attached
via fluid filled tubing to an internal cannula designed to snap into place within the
guide cannula. The internal cannula was back loaded with 5x10 ‘ 5 M angiotensin
II in artificial cerebrospinal fluid (aCSF) solution. The dummy cannula was
replaced with the loaded internal cannula and a 3 pi injection was made. After
approximately

2 0

seconds, the internal cannula was removed and the dummy

cannula replaced. The animal was returned to the cage. The water bottle was
weighed before and approximately 30 minutes following i.c.v. injection. Both time
until onset of drinking and volume drank were assessed. Passing responses
began drinking within 3 minutes of injection and drank >12 ml within 30 minutes
of injection. Often animals failing the initial test passed on successive tests.
Animals repeatedly failing drink tests (5) or considered to be in poor health were
excluded from the study.
At least 24 hours following a successful drink test animals were placed
into 1 of 5 experimental groups. Animals were pre-treated with a catecholamine
synthesis inhibitor (°c-methyltyrosine, 200 mg/kg IP) or saline solution at 90
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minutes prior to decapitation. Approximately 50 minutes prior to decapitation,
internal cannula attached to syringes (Hamilton, 10 pi) and preloaded with

1

of 4

test solutions were placed within the guide cannula as described above. Bolus
injections of 3 (il were delivered at 45, 30, and 15 minutes prior to decapitation
and drinking responses were monitored. Decapitation was accomplished with a
small animal guillotine. Immediately following decapitation, the brain was
removed and dissected into the left cortex, right cortex, hindbrain and midbrain,
forebrain, and cerebellum. Each brain region was weighed and homogenized in 3
ml of homogenizing solution. Following homogenization, an additional 3 ml of
homogenizing solution was added. Tissue samples were then stored at -70°C
until catecholamines were extracted.

Catecholamine Extraction from Brain Homoqenates
Frozen tissue samples were thawed to room temperature and centrifuged
for 25 minutes at 20,000xg (14000 rpm, Beckman J2-21 centrifuge with pre
cooled J20.1 rotor, set=2°C). Following centrifugation, the supernatant from each
sample was collected and stored at -70°C until extraction. Catecholamines were
extracted from tissue samples by differential affinity to acid washed alumina
oxide (AAO). Samples (1ml) were placed into vials containing

1

ml Tris buffer and

50mg AAO and the vials were vortexed and shaken for 1 0 minutes. The liquid
was removed with a Pasteur pipette and the AAO washed twice with deionized
water. With the 3rd wash, the AAO is transferred into a microfiltration apparatus
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and centrifuged (Damon IEC HN-SII model, 3500rpm,

8

minutes) to dryness.

Trichloroacetic acid (200 pi) was added to the AAO and vortexed gently. After 10
minutes, the trichloroacetic acid was collected by centrifugal filtration as before
and stored at -70°C until HPLC quantitation.

HPLC Quantitation of Catecholamines
HPLC quantitation of catecholamines was by electrochemical detection.
Mobile phase was circulated in a closed circuit from a reservoir, through a pump,
injection port, guard column, analytical column, detector flow cell, and returned to
the reservoir. A light helium sparge was maintained through the reservoir to keep
the mobile phase degassed. The electrochemical detector applied a voltage
potential of +70 mV across the mobile phase, causing reduction and oxidation of
active analytes within the mobile phase. After sufficient time, the mobile phase
equilibrated to the applied voltage and freshly introduced analytes oxidized and
reduced above the equilibrium redox rate. Samples were introduced into the flow
at the injector port. The redox current was detected, amplified, and recorded.
HPLC separation of analytes produced gaussian peaks of redox activity on a
current/time plot (chart recorder) with specific retention times for each analyte
separated.
Catecholamine standards were used to tune mobile phase characteristics
for optimum separation and to asses response factors (observed area under
peak per amount of analyte in sample) for each catecholamine of interest and for
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the internal standard. Similarly, standards were extracted to asses the extraction
efficiency (percent of initial catecholamine present in final extract) for each
catecholamine of interest and for the internal standard. Standards were extracted
in buffers of varying pH levels to optimize pH of extraction.
Catecholamine extracts from rat brain tissue homogenates were injected
and the peaks corresponding to NE, EPI, DA, and DHBA analyzed. NE, EPI, and
DA were measured by adjusting the known initial amount of DHBA (internal
standard) in

6

ml of homogenizing buffer. The internal standard amount was

multiplied by the ratio of the areas under the NE, EPI and DA peaks to the area
under the DHBA peak, and by the ratio of the DHBA response factor to response
factors for each of the catecholamines. For example, if a chart trace indicated an
area under a NE peak of 50 volt«seconds and an area for DHBA of 75
volt«seconds, with response factors of 2 .5 3 volt«seconds/ng NE and 3.12
volt«seconds/ng DHBA and an initial amount of DHBA of 300 ng, then
NE = 300 ng • (50 / 75) • (3.1 2 / 2.53) = 247 ng.
The absolute amount of catecholamine was calculated as ng catecholamine per
g tissue.

Materials
0 .1

M Perchloric Acid (H CI04): Dilute 17.1 ml of 70% (concentrated) H C I0 4 to
liters.
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Artificial Cerebrospinal Fluid (aCSF): Into a 100 ml volumetric flask put 1.4960g
NaCI, 0.0388g KCI, 0.0382g CaCI2, 0.0366g MgCI2, 0.3360g N a H C 0 3,
and 0.0697g Na 2 H P 0 4. Dilute to the mark and stir until dissolved. Dilute
this solution

1 :1

when preparing agents in this vehicle.

Carrier free monoiodinated

125

l-[sar 1 ,ile8]-angiotensin II: supplied by Dr. Robert

Speth, was prepared as described previously (Speth etai., 1987).
Catecholamine Standard Solutions:
DHBA (100mg/L): Dissolve 16mg DHBA*HBr into 100 ml of 0.1 M
perchloric acid (H C I0 4).
NE (75 mg/L) / EPI (25 mg/L): Dissolve 14.2 mg norepinephrine bitartrate
and 4.6 mg epinephrine bitartrate into 100 ml of 0.1 M perchloric
acid (H C I0 4).
(100 ng DHBA, 75 ng NE, 25 ng EPI, 100 ng D A /m l): Combine 100 pL of
each of the proceeding catecholamine standard solutions and dilute
to 100 ml with 0.1 M perchloric acid (H C I0 4).
Homogenizing Solution: Combine 14.15 g/L monochloroacetic acid, 4.5 g/L
sodium hydroxide and 0.75 g/L disodium EDTA. Dissolve and adjust the
pH to 3.00 - 3.05 with solid monochloroacetic acid or sodium hydroxide.
Add pargyline to 350 pM (68.5 mg/L).
HPLC Mobile Phase: Dissolve 14.15 g/L monochloroacetic acid, 4.5 g/L sodium
hydroxide and 0.75 g/L disodium EDTA. Adjust the pH to 3.00 to 3.05
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using solid monochloroacetic acid or sodium hydroxide. Add 65 mg/L
sodium octyl sulfate.
Phosphate Buffered Saline: Add 8.5 g/L sodium chloride to 10 ml/L 500 mM
sodium phosphate dibasic. Adjust pH to 7.2 to 7.3.
Subbing Solution: To 500 ml of water, add 5 g gelatin. Warm to dissolve but do
not exceed 60°C. To 500 ml of water, add 0.5 g chromium potassium
sulfate (CrK(S 0 4 )2 :1 2 H 2 0 ). After both solutions have dissolved, mix
together and filter. Add thymol to preserve and refrigerate. Warm to room
temperature before using and filter after each use.
Thionin staining solution: To 600 ml boiling water, add 3.6 ml glacial acetic acid,
1.0 g thionin and 3.2 g Sodium Acetate (0.8%). When dissolved, add 400
ml deionized water and adjust the pH to 4.5 with 10 N Sodium Hydroxide.
Losartan potassium and P D 123177 were supplied by Dr. Ronald Smith of
DuPont (Wilmington, DE). Angiotensin peptides were obtained from Bachem
(Torrance, Ca). Glacial acetic acid (A38c-212), EDTA, ethyl alcohol (A962p-4),
sodium chloride (S671-3), sodium hydroxide (S-318), sodium phosphate dibasic
(BP-331-1) and monobasic (S381), thionin stain (T-409), trichloroacetic acid
(A176), and xylene (X3s-4) were obtained from Fisher Scientific (Pittsburgh, PA).
Amastatin (A-1276), bacitracin (B-0125), bestatin (B-8385), BSA (A-7906;
albumin, bovine, fraction V), catecholamine standards (dihydroxybenzylamine DHBA, epinephrine, norepinephrine, and dopamine), dithiothreitol (DTT, D-0632),
pargyline (P-8013), 1,10 phenanthroline (P-1294), phenylmethylsulfonyl fluoride
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(PMSF, P-7626), sigmacote (SL-2), and trizma base (T-1503) were obtained
from Sigma Chemical Co. (St. Louis, MO).
Leupeptin was obtained from Cambridge Research Biochemicals, Inc.
(Wilmington, DE). Eukitt mounting medium was obtained from Aldrich chemical
company (Milwaukee, Wl). Sodium octyl sulfate, rapid fixer, D-19 developer, and
Photo Flo were obtained from Kodak-Eastman chemical company (Rochester,
NY).
Guide cannula (22 ga cut 5 mm below pedestal), internal cannula (28 ga
to fit guide with

1

mm projection), dummy cannula, cannula connectors, drill bits

(for 0-80 screws), and jeweler’s screws (2.4 mm length, 0-80 x 3/32) were
obtained from Plastics One Inc. (Roanoke, Va).
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CHAPTER 4
EVALUATION O F BUFFER C O N STITU EN TS FO R DIFFERENTIAL EFFECTS
ON

12 5

I[S A R \ ILE8]-ANG IO TENSIN II BINDING A T A ^ AND AT 2 RECEPTORS
IN TH E RAT BRAIN

Introduction
Two subtypes of angiotensin II (All) receptors have been identified
(Whitebread etai., 1989; Chiu etai., 1989a). The A ^ receptor subtype is
differentiated by high affinity (IC 5 0 = 10 ‘ 8 M) for losartan (DuP753) and similar
compounds, and relatively low affinity for CGP 4 2 1 12A and PD123177 (IC 5 0 =
10 "4 M). These compounds show the opposite pattern of selectivity for the
receptor subtype designated A T2. Receptor autoradiographic techniques have
confirmed the presence of both All receptor subtypes in discrete nuclei within the
brain (Rowe etai., 1990c; Gehlert etai., 1990; W am sley etai., 1990; Song etai.,
1992; Tsutsumi and Saavedra, 1992).
Several laboratories using membrane preparations or receptor
autoradiography have employed a variety of procedures to investigate All binding
with the implicit assumption that the basic methodology does not have a
detrimental effect on binding to the All receptors of interest. This has not always
been the case. For example, early studies indicated that sulfhydryl reducing
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agents were required to protect the radioligand from degradation (Glossman et
a i, 1974; Bennett and Snyder, 1976) and they increased binding affinity for

125

l-

All in brain tissue (Chen et at., 1982; Printz, 1987). Thus sulfhydryl reducing
agents were widely used in binding assays for brain tissue until it was revealed
that they severely impair binding specifically at AT, but not AT 2 receptors
(Whitebread e t a i , 1989; Chiu etai., 1989b; Speth e t a i , 1991). Accordingly,
most investigators now exclude sulfhydryl reducing agents when studying All
receptors.
Most investigators are in general agreement with respect to localization
and distribution of All receptor subtypes in brain tissue and the relative affinities
of various ligands at AT-i and AT 2 sites. However, subtle differences are apparent
with respect to relative binding density among brain nuclei in autoradiographic
studies. Further, we have reported that the radioligand

125

l-[sar\ile8]-AII

( 1 2 5 I-SIAII) has a fourfold selectivity for brain A Ti binding sites (Rowe e t a i ,
1992) which is not corroborated by other investigators (Chang e t a i , 1990;
Obermuller e t a i , 1991). Prompted by the precedent set with sulfhydryl reducing
agents, we became concerned that different buffer constituents, used in binding
assays in different laboratories, might affect binding differentially at A Ti and AT2
sites. Inclusion or exclusion of such a factor in incubation cocktails might alter
results obtained in different laboratories. W e began by investigating the
peptidase inhibitors used routinely in our autoradiographic studies, bacitracin and
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EDTA, and then evaluated phenanthroline and BSA, which have been used by
other investigators (Koziarz and Moore, 1989; Chang etai., 1990).

Design

Evaluation of EDTA and Bacitracin
Studies in our laboratory have routinely used buffer containing 150 mM
NaCI, 50 mM sodium phosphate (pH=7.1-7.2), 5 mM disodium ethylenediamine
tetraacetate (EDTA), and 0.1 mM bacitracin. Sets of six adjacent sections were
prepared from each of

6

rat brains. These were incubated either in the above

buffer (containing EDTA and bacitracin), a buffer from which bacitracin was
omitted, and a buffer from which EDTA was omitted. Total and nonspecific
binding were determined for each of the three buffers by in vitro receptor
autoradiography as described in Chapter 3 - Methods.

Evaluation of Phenanthroline and BSA
A second experiment compared our standard buffer (NaCI, NaP 0

4

, EDTA,

and bacitracin) versus a buffer in which EDTA and bacitracin were replaced with
1,10 phenanthroline (5x1 O'4 M) and BSA (0.2%), and one in which no peptidase
inhibitors were present (EDTA and bacitracin were omitted). Sets of six adjacent
sections prepared from each of 5 rat brains as described above were incubated
in each of the 3 study buffers with and without an excess of unlabelled All. Again,
specific binding was assayed by in vitro receptor autoradiography.
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Binding was also compared in buffers containing phenanthroline or BSA
alone (versus phosphate-saline buffer, N= 6 ) at the nucleus of the solitary tract
(AT-i) and the inferior olivary nucleus (AT2).

Screening of Individual Buffer Constituents
To determine the individual effects on A ^ and AT 2 binding of additional
buffer constituents, total binding (N=3) was determined in a series of
brain sections. Total

125

6

adjacent

I-SIAII binding in control buffer (NaCI, N a P 0 4) was

compared to total binding in the presence of individual peptidase inhibitors
(dithiothreitol (DTT), 5 mM; PMSF,

1

mM; amastatin, 1.25 mg/L; bestatin, 1.25

mg/L; leupeptin, 1.25 mg/L). Total binding was determined by in vitro receptor
autoradiography for predominantly A ^ and A T 2 nuclei.

Data Analysis and Statistics
Brain nuclei were selected and categorized by subtype predominance
(>90% ATi or AT2) based on a previous study (Rowe etal., 1992) to facilitate
comparisons of buffer effects on the two subtypes. ATi nuclei used include the
piriform cortex (PC), suprachiasmatic nucleus (SCh), medial pre-optic nucleus
(MnPO), ventral hippocampus (Vhip), paraventricular nucleus of the
hypothalamus (PV), and the anterior pituitary (Pit). The AT 2 nuclei used are the
medial geniculate nucleus (MG), superior colliculus (SC), subthalamic nucleus
(STh), lateral septum (LS), and the mediodorsal thalamus (MD). Subtype
selective competitors were not used for this study.
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For each experiment, buffer effects on binding at each nucleus and
recovery of intact radioligand were evaluated by a repeated measures analysis of
variance and a modified Newman-Keuls test according to Winer (1971).

Results
Table 4-1A describes radioligand integrity after incubation with brain slices
as a percent of intact radioligand prior to incubation in three buffers differing with
respect to the presence of EDTA and bacitracin. HPLC analysis determined
nearly complete recovery of intact

125

I-SIAII from buffer containing both bacitracin

and EDTA and in buffer containing only bacitracin following incubation of rat
brain slices. However, intact radioligand recovery was significantly decreased
(p<0.05) in the absence of bacitracin. Table 4 -1 B compares

125

I-SIAII binding at

rat brain nuclei in these three buffers. Figure 4-1 depicts specific binding as a
percent of specific binding in buffer containing both EDTA and bacitracin at
predominantly A L and AT 2 nuclei. The exclusion of EDTA consistently caused a
significant (p<0.01) reduction in specific

125

I-SIAII binding in all A ^ and AT 2

predominant brain nuclei studied, with an average reduction of approximately
40% . Non-specific binding (not illustrated) was also consistently lower at all
nuclei, averaging 17% less, with the omission of EDTA, but the effect was
significant at only three nuclei. The exclusion of bacitracin had no effect on
specific or non-specific binding at either category of brain nuclei.
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TABLE 4-1. 12 5 I-[S A R \IL E 8]-AII R E C O V E R Y AND SPECIFIC BINDING IN
BUFFERS CONTAINING BACITRACIN AND/OR EDTA

A.

Radioligand Recovery

B.

+Bac
(-EDTA)
98 ± 3%

ns

+EDTA
+8ac
98 ± 1 %

•

+EDTA
(-Bac)
83 ± 7%

Radioligand Binding

Predominantly
Piriform Cortex
Suprachiasmatic n.
Median Preoptic
Ventral Hippocampus
Paraventricular n.
Anterior Pituitary

311 ±
715±
493 ±
496 ±
604 ±
2787 ±

72
59
98
67
73
359

Nuclei:
• *
* *

• *
• *
* *

611 ± 1 3 4
1 0 4 9 ± 79
887 ±111
700 ±101
1 1 4 0 ± 87
4690 ± 484

ns
ns
ns
ns
ns
ns

667 ±171
9 5 3 ± 63
8 7 8 ± 79
679 ± 70
10 1 4 ± 87
4368 ± 4 1 9

ns
ns
ns
ns
ns

346
805
441
591
286

Predominantly AT2 Nuclei:
Mediodorsal Thalamus
Subthalamic n.
Medial Geniculate n.
Superior Colliculus
Lateral Septum

226
581
318
304
141

±19
± 42
±59
± 28
±24

* *
* *
* *
* *
« •

372
887
468
577
260

±
±
±
±
±

25
80
56
56
24

±
±
±
±
±

27
52
65
52
24

Binding values are reported in fmoles/gram of brain tissue ± SEM (n= 6 ). * and **
denote significant differences (p<0.05 and p<0.01, respectively) between values
in adjacent columns.

Because our recoveries exceeded 80% with reduced peptidase inhibition,
we elected to utilize a minimal control buffer in the evaluation of additional buffer
constituents. Table 4-2 summarizes radioligand integrity (A) and binding
determinations (B) in buffers containing bacitracin and EDTA, no peptidase
inhibitors, or phenanthroline and BSA. T h e radioligand was well preserved by the
bacitracin/EDTA buffer and by the phenanthroline/BSA buffer. Intact

12 5

I-SIAII

recovery was significantly reduced (but still exceeded 80%) in the buffer
containing no peptidase inhibitors, consistent with the first experiment showing
that deletion of bacitracin from the buffer led to increased radioligand
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Binding at AT, Nuclei

RAT

B R A IN

NUCLEI

Binding at AT2 Nuclei

a

I ill I

MO

S-Th.

RAT
1 0 0

%

+ E D T A /b a citra c in

MG

B R A IN

|—

SC

LS

NUCLEI

|

- EDTA

- bacitracin

Figure 4-1. Effects of EDTA and bacitracin on specific 1 25|_siAII binding. The
100% line represents specific binding in the presence of bacitracin and EDTA,
while white bars depict binding in the absence of EDTA and the black bars depict
binding in the absence of bacitracin. Significant differences (p<0.01) from the
control line are noted. Data are expressed as means ± SEM (N= 6 ).
Abbreviations: PC, piriform cortex; S.CH., suprachiasmatic n.; MnPO, median
preoptic n.; V.Hipp., ventral hippocampus; PV, paraventricular n.; Pit., anterior
pituitary; MD, mediodorsal thalamus; S.Th., subthalamic n.; MG, medial
geniculate n.; SC, superior colliculus; and LS, lateral septum.
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TABLE 4-2. SPECIFIC 1 2 5 l-[SAR 1 ,ILE8]-ANGIOTENSIN II R E C O V ER Y AND
SPECIFIC BINDING IN BUFFERS CONTAINING PHENANTHROLINE/BSA,
BACITRACIN/EDTA, OR NO INHIBITORS
+Phen
+BSA
A. Radioligand
Recovery

94 ± 4%

+Bac
+EDTA
Ns

97 ± 1%

no
inhibitors
*

86 ± 4%

B. Radioligand Binding

Predominantly A ti Nuclei:
Piriform Cortex
Suprachiasmatic n.
Median Preoptic
Ventral Hippocampus
Paraventricular n.
Anterior Pituitary

1061 ± 225
1553 ± 334
1331 ± 217
1055 ± 117
1542 ± 191
6285 ± 1 4 4 9

ns
**
•
•-»
* *

**

1026 ± 2 7 3
1072 ± 2 4 8
1024 ± 1 7 0
817 ± 1 0 0
1015 ± 124
4100 ± 7 8 0

*
*

**
*

5 7 8 ± 112
769 ± 1 8 6
6 2 2 ± 51
4 8 5 ± 43
5 9 4 ± 89
2598 ± 750

Predominantly AT2 Nuclei:
Mediodorsal Thalamus
Subthalamic n.
Medial Geniculate n.
Superior Colliculus
Lateral Septum

167
590
245
347
152

± 8
± 75
±18
± 48
± 9

**

*«
• *
««

289
825
319
458
239

±13
± 93
± 24
± 62
± 32

*
« *
* *
• »
* *

240 ± 21
492 ± 48
189 ± 2 0
253 ± 33
115 ± 8

Binding values are reported in fmoles/gram of brain tissue ± SEM (n=5). * and **
denote significant differences (p<0.05 and p<0.01, respectively) between values
in adjacent columns.

degradation. Figure 4-2 illustrates relative specific binding determinations in each
of these buffers at predominantly ATi and predominantly AT 2 nuclei. In the
presence of both EDTA and bacitracin, binding was increased (compared to
binding in the absence of inhibitors) by an average of 39% at all brain nuclei
surveyed irrespective of subtype composition. At all predominantly A ^ nuclei
(except the piriform cortex), binding was significantly higher in the
phenanthroline/BSA buffer compared to both other buffers. In contrast,

125

I-SIAII

binding at AT 2 nuclei in the phenanthroline/BSA buffer was significantly lower
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Binding at AT, Nuclei
$

o
CJ
z

i

m
CJ

y.
U

PC

S.CK

%

fw TfO

RAT

VH ipp.

PV

pit

B R A IN NUC LEI

Binding at AT2 Nuclei
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T
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+ EDTA/bacitracIn
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RAT
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B R A IN N U C LEI

C=]
No additions

Phenanthroline/BSA

Figure 4- 2. Effects of phenanthroline and BSA on specific 1 2 5 I-SIAII binding.
The 100% line represents specific binding in the presence of bacitracin and
EDTA, while the white bars depict binding in the absence of peptidase inhibitors
and the black bars depict binding with phenanthroline and BSA. Significant
differences (* p<0.5, and ** p<0.01) from the 100% control line are noted. Data
are expressed as means ± SEM (N=5). See brain nuclei abbreviations in the
legend of Figure 4-1.
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than EDTA/Bacitracin and similar to the buffer with no additions. Thus, the
EDTA/bacitracin buffer affected binding consistently at ATt and AT 2 binding sites
while the phenanthroline/BSA combination enhanced binding preferentially at
A ^ sites. Non-specific binding (not presented) was similar in all three buffers and
was approximately 10-15% of total binding. Phenanthroline and BSA were
evaluated individually at the nucleus of the solitary tract and the inferior olivary
nucleus in each of

6

rat brains. Specific binding at the nucleus of the solitary tract

(AT!) was 782 ± 52 fmol/g in phosphate-saline buffer, 1224 ± 93 with BSA (57%
increase, p<0.01), and 1122 ± 7 8 with phenanthroline (43% increase, p<0.01).
Specific binding at the inferior olivary nucleus (AT2) was 410 ± 30 fmol/g in
phosphate-saline buffer, 356 ± 23 with BSA (NS), and 325 ± 24 with
phenanthroline (21% decrease, p<0.01). Thus, the enhancement seen with
phenanthroline and BSA at A ^ nuclei in the previous experiment is due to
individual contributions by both phenanthroline and BSA.
Additional buffer constituents were screened and the results are
summarized in table 4-3. Radioligand recoveries were significantly less than
1 0 0

% (after tissue incubation compared to before tissue incubation) in the

presence of PMSF, amastatin, or leupeptin. Similarly, recovery in the control
buffer (saline-phosphate) was 76 ± 9.1 % (p<0.05). Only DTT seem ed to offer
substantial protective effects.
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TABLE 4-3. 1 2 5 I-[S A R \ ILE8]-ANGIOTENSIN II RECOVERY
AND TOTAL BINDING (RELATIVE TO CONTROL) IN THE
PRESENCE O F IND IVID U AL PEPTIDASE INHIBITORS.
DTT
A. Radioligand Recovery
87 ± 5.8%
Significance
Ns
(vs. 1 0 0 %)

PM SF

Amastatin

Bestatin

Leupeptin

69 ± 4 .2 %

77 ± 6.2%

76 ± 1 1 .0 %

73 ± 1 0 .9 %

P<0.01

P<0.05

ns

P <0.05

115 ± 6 . 1
108 ± 5 .3
107 ± 9 .2
1 1 0 ± 6 .3
104 ± 2 . 1

124 ± 10.9
99 ± 4.2
106 ± 9.2
6.7
1 0 2 ±
111 ±
7.6

109 ± 1 .7

108 ±

B. Total Binding (% Control) 1
Predominantly A ^ Nuclei
14 ± 0.05
PC
1 0 2 ± 0 .2
107 ± 1 .6
Pit
1 2 ± 2 .1
104 ± 1 .2
96 ± 3.8
105 ± 3 .4
PV
24 ± 2 .8
103 ± 1 .1
13 ± 0 .8
95 ± 5 .1
SCh
97 ± 3.4
98 ± 4 .1
14 ± 2 .2
96 ± 4 .1
VHipp.
A T t Mean

LS
MD
MG
SC
STh.
AT2 Mean
Selectivity
(AT 1 vs. AT2)

15 ± 2 .2

131
124
111
139
109

1 0 0

±

1 .8

100 ± 2 .5

Predominantly AT2 Nuclei
117 ± 5 .7
112 ± 4 .4
± 1 9 .6
102 ± 1 .7
± 5.4
109 ± 1 .4
97 ± 7.6
108 ± 7 .5
± 8.1
94 ± 5.6
95 ± 3 .5
± 2 5 .0
± 7.0
107 ± 6 .2
110 ± 7 .4

123 ±

5.8

P<0.05

105 ± 3 .1

106 ± 4 .2

ns

ns

130
116
114
116
117

± 1 7 .2
± 4.5
± 10.5
± 3.4
± 14.4

119 ±

ns

2.8

150
119
119
132
119

4.4

± 2 5 .7
± 1.5
± 13.8
± 5.6
± 8.3

128 ±

ns

Abbreviations: piriform cortex (PC), pituitary (Pit), paraventricular n. of the
hypothalamus (PV), suprachiasmatic n. (SCh), ventral hippocampus (VHipp.),
lateral septum (LS), mediodorsal thalamus (MD), medial geniculate (MG),
superior colliculus (SC) and subthalamic n. (STh.).
1
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Binding values are expressed as percent of binding observed in control
buffer to facilitate comparisons between nuclei, in order to ascertain the
selectivity (differential effects on binding with respect to receptor subtype), the
effect on binding at predominantly ATi nuclei is compared to that observed at
predominantly AT 2 nuclei. Dithiothreitol (a sulfhydryl reducing agent) altered
binding as expected, markedly inhibiting ATi binding while enhancing binding at
AT 2 sites. This pattern produced a significant difference in relative binding at ATi
versus AT 2 sites. Relative binding in the presence of PMSF, amastatin, bestatin
and leupeptin was not significantly different with respect to receptor subtype.
Therefore, these peptidase inhibitors do not differentially affect binding at ATt
and AT 2 receptors.

Discussion
Analysis of receptor binding studies ideally presupposes that ligand and
receptor metabolism do not occur. Selection of incubation constituents is often
made to accomplish this goal with the expectation that these constituents will not
interfere with the receptor-ligand reaction. The susceptibility of angiotensin II and
its analogues to metabolism dictates the use of peptidase inhibitors in incubation
cocktails. Some laboratories use radioligands such as

125

I-SIAII which are

relatively resistant to aminopeptidase action. There is considerable variation in
the selection of inhibitors for other peptidases and for other ionic buffer
constituents. With regard to the criterion that constituents must not interfere with
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binding, many of these procedures were established before the discovery of All
receptor subtypes and it is now apparent that this criterion was not satisfied
independently for both ATi and AT 2 binding reactions. This important
consideration was emphasized by the discovery that sulfhydryl reducing agents
selectively interfere with binding at ATt sites (Whitebread etal., 1989; Chiu et
al., 1989b; Speth etai., 1991).
In our studies of rat brain All receptor binding we have noted some subtle
differences in data reported by various laboratories. For example, estimates of
receptor subtype proportions within brain nuclei are not entirely consistent (Rowe
e t a i , 1992; Gehlert etal., 1990; Song e t a i , 1992; Tsutsumi and Saavedra,
1992). Moreover, we find that

125

I-SIAII shows some selectivity for brain ATt

receptors (Rowe et a i, 1992) which is at variance with findings from some
laboratories (Chang e t a i , 1990; Obermuller e t a i , 1991) but is similar to the
findings of Tsutsumi and Saavedra (1992) for

125

l-sar1 -AII. It occurred to us that

such discrepancies might result from one or more peptidase inhibitors exerting
differential effects on binding at ATi and AT 2 receptors similar to that observed
for sulfhydryl reducing agents. Table 4-4 itemizes incubation constituents used
by several laboratories.
Comparison of binding at A ^ and AT 2 sites was accomplished by sorting
brain nuclei by predominant subtype (>90%) established in a previous study
(Rowe e t a i, 1992). Thus, the results were not obtained from completely
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TABLE 4-4. ITEM IZED LISTING O F BUFFER
C ONSTITUENTS FOR SEVERAL LABORATORIES.

1

2

3

Sodium phosphate (mM)
Tris (mM)
NaCI (mM)
MgCI2 (mM)

50

50

10

EDTA (mM)
EGTA (mM)
Bacitracin (mM)
BSA (%)
Phenanthroline (mM)

5

150

150
10

5
0.1
0.4

Reference1:
4
52
10

6*

r

50
125

50
150

5

10

150

120

100
6.5

5

5

5

1

0.2

0.4
0.2

0 .07
0.2
0.09

0.1
0.2

0.2
1

1References: 1> Rowe eta l., 1992; 2> G ehlert e ta l., 1990; 3> Song etal., 1992; 4> Tsutsumi and
Saavedra, 1992; 5> Chang etal., 1990; 6> O berm uller etal., 1991; 7> Koziarz and Moore, 1989.
Additional buffer constituents:2 0.2 mg/ml soybean trypsin inhibitor, 0.1 mM phenylmethylsulfonylfluo rid e ;3 1.25 pg/ml each antipain, phosphoramidon, leupeptin, pepstatin A, bestatin and amastatin;
i 1 mM phenylrr.ethylsulfonylfluoride.

homogeneous receptor subtype populations. This approach was selected
because utilization of subtype selective antagonists to mask each receptor
subtype would introduce uncertainties with respect to possible differential
metabolism or binding characteristics of antagonists in each experimental
situation. W e believe the approach is justified by the compelling internal
consistency observed within the A ^ and AT2 categories.
W e first evaluated the buffer constituents routinely used in our laboratory,
EDTA and bacitracin. Addition of EDTA quantitatively increased specific binding
by approximately 70% equally at both AT-i and AT2 binding sites. This is
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interesting because radioligand degradation was unaffected by the absence or
presence of EDTA, suggesting that EDTA affects binding in a manner unrelated
to radioligand preservation. Three possible mechanisms might be considered:
1) EDTA chelates ions that hamper the interaction of 125I-SIAII with both All
receptors, 2) EDTA interacts directly with the radioligand (and/or receptors) to
enhance binding affinity, or 3) EDTA inhibits metalloproteases that degrade both
ATt and AT 2 receptors equally. The effect of EDTA on non-specific binding is
similar. If we assume this is not residual specific binding, then EDTA affects
125I-SIAII but not All receptors.
Bacitracin appears to be important for preserving radioligand, but had no
effect on specific or non-specific binding. However, radioligand metabolism in the
absence of bacitracin was minimal (13-17%) which probably accounts for our
inability to observe differences in radioligand binding in the presence and
absence of bacitracin. The presence of bacitracin may assume greater
importance for the preservation of other angiotensin peptides and in binding
assays where tissue/ligand ratios are higher. Parenthetically, concentrations of
bacitracin greater than 0.1 mM inhibit 125I-A1I binding in rat brain homogenates
(Speth, unpublished observation).
Some investigators use phenanthroline (0.1-1.0 mM) and BSA (0.2% ) in
binding assays (table 4-4). Koziarz and Moore (1989) evaluated 125I-AII binding
with bovine membrane preparations in the absence and presence of
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1,10-phenanthroline (1 mM). Phenanthroline completely eliminated 125I-AII
degradation without affecting binding. Since similar results were obtained for both
uterine (AT2 predominant) and aortic (A ^ predominant) preparations, we infer
that binding was not differentially affected at A ^ and AT2 sites. These interesting
observations prompted us to include phenanthroline in our autoradiographic
system. W e used a concentration of 0.5 mM phenanthroline which is lower than
that used by Koziarz and Moore (1 mM) but higher than that used by Chang et al.
(1990), (0.09 mM). Radioligand recovery in this study was 86.7% in the absence
of inhibitors compared to 94.3% (not significantly different) in the presence of
phenanthroline and BSA. The excellent radioligand recovery in the absence of
inhibitors in our experiments may be attributed to the aminopeptidase resistance
of the sarcosine substituted radioligand and the low tissue/radioligand ratio in
these autoradiographic studies. Interestingly, however, phenanthroline and BSA
had marked differential effects on binding at ATi nuclei as compared to AT2
nuclei.
Addition of phenanthroline and BSA affects binding at both A ^ and AT2
sites in a manner that is dissimilar to EDTA. Phenanthroline chelates metal ions
(Mertell and Calvin, 1956), but none that are not also chelated by EDTA. Thus,
the chelating properties of phenanthroline are unlikely to account for the
differential effects on binding. It is also possible that BSA contributes to the
observed effects. The A T t receptor has disulfide bonds in its extracellular domain
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(Murphy etal., 1991; Sasaki etal., 1991) that are crucial for binding (Whitebread
etal., 1989; Chiu etal., 1989b). Since BSA is stabilized by 17 disulfide bonds
(Budavari, 1992) it might serve as an antireductant and preserve the tertiary
structure of the ATi receptor. W e have not attempted a systematic analysis of
each buffer constituent employed by multiple laboratories but we do provide
evidence that procedural differences are likely to account for reported differences
in binding characteristics.
This study indicates that degradation of 125I-SIAII is minimal (<17% ) in the
complete absence of peptidase inhibitors in our autoradiographic procedures. It
does not follow, however, that the observation is applicable to nonautoradiographic binding studies or to autoradiographic studies using nonsarcosine angiotensin peptides or to studies with higher tissue/incubation
medium ratios. Inclusion of bacitracin or phenanthroline/BSA leads to near total
recovery of radioligand. EDTA enhances binding but does so uniformly at both
A ^ and AT2 sites. In contrast, phenanthroline and/or BSA markedly enhance
binding at ATi sites but not at AT2 sites. It is clear that buffer constituents affect
binding at A ^ and AT2 sites by mechanisms that are independent of radioligand
metabolism. Therefore, relative binding characteristics between A ^ and A T2
receptor subtypes will necessarily differ and caution must be exercised in
comparing data from different laboratories.
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CHAPTER 5
LOCALIZATION AND SUBTYPE CHARACTERIZATION O F ANGIOTENSIN II
RECEPTORS IN THE N O R M O TEN SIVE AND SPONTANEOUSLY
H YP ER TEN SIVE HAMSTER

Introduction
The presence of angiotensin II (All) receptor subtypes has been confirmed
in tissue homogenates of rat, rabbit and monkey brains (Chang and Lotti, 1991),
and classification of individual brain nuclei by receptor subtype has been
determined in the rat (Rowe et al., 1990c; 1991; 1992). Subtype classification of
individual brain nuclei remains undetermined for other species, but binding sites
have been mapped autoradiographically to individual brain nuclei in the sheep
(McKinley et al., 1986), rabbit (Mendelsohn et al., 1988), dog (Speth et al., 1985),
and human (McKinley et al., 1987). Some species differences are evident but
binding site distributions are generally similar (Mendelsohn et al., 1990). The
purpose of the first part of the present study is to define the distribution of All
receptors in the hamster brain, and further, to classify each receptor population
by receptor subtype.
Genetic models of hypertension in the rat are associated with
disturbances in the brain angiotensin system. For example, centrally

49
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administered All stimulates a larger blood pressure increase in spontaneously
hypertensive rats (SHR) than in normotensive control rats (Hoffman etal., 1977),
and saralasin administered centrally reduces the blood pressure of SHR but not
control rats (Hutchinson etal., 1975; Phillips etal., 1977). Further, there is a
greater All-like immunoreactivity (Weyhenmeyer and Phillips, 1982), and
quantitative autoradiographic studies have shown significantly higher All binding
in SHR brains (Hwang et al., 1986; Gehlert etal., 1986b). W e therefore
compared 125l-[sar1,ile8]-AII ( 125I-SIAII) binding in a model of genetically
hypertensive hamster (Joyner etal., 1988) with normotensive controls.

Design
The first experiment was designed to determine which hamster brain
nuclei contain All receptors, and further to characterize each receptor population
by All receptor subtype. Brains from 4 golden Syrian hamsters (102-120 g) were
prepared as described in methods (in vitro receptor autoradiography). Incubation
mediums consisted of buffer with 125I-SIAII (350-420 pM) alone, with losartan
(10'5 M), with PD 123177 (10‘5 M), or with All (10'6 M). Tissue sections from two
animals were also incubated in the presence of both losartan and PD 123177
(10'5 M). Receptor subtype distribution was determined by comparing specific
binding of 125I-SIAII in the presence of losartan or PD 123177 with specific binding
in the absence of competitors. The subtype selective compound losartan
competes for 125I-SIAII binding at the A ^ but not at the AT 2 subtype while
PD 123177 competes selectively for the AT2 binding site.
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A second experiment evaluated 125I-SIAII binding in a hamster model of
genetic hypertension (Joyner etal., 1988). Brain sections from 4 normotensive
(128-133 g) and 4 hypertensive (117-144 g) hamsters were incubated with
125I-SIAII (262-266 pM) as described in methods (in vitro receptor
autoradiography). Each brain from a hypertensive hamster was processed and
incubated concurrently with a brain obtained from the normotensive control
strain.

Results
Sets of adjacent sections were incubated with 125I-SIAII in the presence
and absence of the All subtype selective compounds losartan (ATi selective) and
PD 123177 (AT2 selective). A typical example obtained at the level of the
hypothalamus is illustrated by the autoradiograms in Figure 5-1. Losartan
(10'5 M) competed effectively for binding sites in the hippocampus, choroid
plexus, and the paraventricular nucleus of the hypothalamus (A T t sites), but not
at the medial habenular nucleus (AT2 site). Competition with PD123177 (10‘5 M)
produced the opposite pattern, i.e. it competed substantially for 125I-SIAII binding
at the medial habenular nucleus, but not at the other structures. The 125I-SIAII
binding was substantially displaced in all structures in sections incubated with
both subtype selective compounds and produced autoradiograms very similar to
those of sections incubated with All (1CT6 M). Similar results were obtained for
various brain nuclei (autoradiograms not illustrated) which were quantitated and
summarized in Table 5-1. A reciprocal competition pattern between the two
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Figure 5-1. [125l][Sar1,lle8]-angiotensin II (125I-SIAII) binding with subtype selective
competitors in adjacent hamster brain sections. A: total 125I-SIAII binding without
competitors; B: thionin stained section (Bar = 2 mm); C: sites insensitive to
losartan (10*5 M ) [medial habenula (MHb)]; D: competition with both losartan (10‘5
M) and PD 123177 (10'5 M); E: sites insensitive to PD 123177 (10*5 M)
[hippocampus (Hip), choroid plexus (ChP), and the [paraventricular nucleus of
the hypothalamus (PV)]; F: non-specific binding not displaced by Ang II (lO"6 M).
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subtype selective compounds was evident in all brain regions. In some brain
nuclei, competition by the combination of both subtype selective compounds was
slightly more effective than All. This is reflected by negative specific binding
values reported in Table 5-1.
Figures 5-2 through 5-6 illustrate 125I-SIAII binding without competitors for
a selection of brain regions listed in Table 5-1. Each autoradiogram is
accompanied by the adjacent thionin stained section to aid in the verification of
structures.

Hindbrain:
Figure 5-2 illustrates 125I-SIAII binding in the dorsal motor nucleus of the
vagus (DMV), the nucleus of the solitary tract (NTS), and the spinal trigeminal
tract. All three regions contain predominantly ATi receptor sites (Table 5-1).
Binding to A ^ sites is also evident in the area postrema (not illustrated) and is
particularly dense in the paramedial segment of the NTS. The remaining
subdivisions of the hamster NTS show modest binding compared to strikingly
dense binding in the DMV. Interestingly, the DMV of the hamster was unique in
that approximately one-fifth of specific 125I-SIAII binding was not displaced by
either losartan or PD123177 at the concentrations used. The lower panel in
figure 5-2 also shows binding in the choroid plexus (ChP) of the fourth ventricle
and a diffuse AT 1 binding is barely discemable in the rostral portion of the
ventrolateral reticular formation. There is a notable absence of 125I-SIAII binding
in the inferior olive.
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TABLE 5-1. [125I][SAR1 ,ILE 8]-A N G I0T E N S IN II BINDING AT HAMSTER
BRAIN NUCLEI W ITH AND W IT H O U T SU BTYPE SELECTIVE C O M PETITO R S
Specific ’“^ l-fs a r’ .ile^-Angiotensin II bound

Nonspecific

(fmoles/g tissu e )1
W ithout

W ith Losartan W ith PD123177

Binding
Losartan

W ith All

+-PD123177

lO ^M

Nucleus

Competition

Pituitary

881± 69

31 2 *7 3 (65%) 715±105 (19%)

67 ± 5 2

111 ± 1 1

Subfornical Organ

1064±201

353±64 (67%) 715±110 (33%)

-46 ± 59

119 ± 34

Median Preoptic n.

706± 90

159±24 (77%)

-13*23

73 ± 11

Paraventricular n.

1263±140

Ventral Hippocampus

651± 79

9 2 *2 6 (86%)

551 ± 5 9 (15%)

Solitarius

955± 48

36 2 *4 4 (62%)

800± 78 (16%)

96 ±11

116 ±

8

Spinal Trigeminal n.

539± 38

169*18 (67%)

389± 35 (28%)

4.5 ± 11

68 ±

6

Pedunculopontine Tg. n.

596± 72

9 2 *8 .9 (85%) 479± 47 (20%)

-19 ± 1 5

66 ± 1 2

Parabrachial n.

746± 15

231 ±22 (69%)

440± 22 (41%)

20 ±

8

73 ± 1 0

Locus Coeruleus

5 3 6 * 19

365±13 (32%)

264± 60 (51%)

7 ±

6

54 ±

6

Inferior Colliculus

682± 74

494±47 (28%)

134± 18 (80%)

11*3

68 ±

7

Superior Colliculus

8 0 0 * 48

686±37 (14%)

105± 14 (87%)

16 ± 17

58 ±

5

Lateral Septum

532± 67

481 ±73 (10%)

115± 23 (78%)

26 ± 2 3

70 ±

7

Medial Geniculate n.

655± 78

108±10 (84%)

484± 40 (26%)

11 ±

69 ±

5

Dorsal Motor n. Vagus

2184±122

Peri-aqueductal Grey

4 4 5 * 36

330±22 (26%)

147± 27 (67%)

Interpeduncular n.

821± 37

587±96 (29%)

96± 24 (88%)

Choroid Plexus

3 8 7 * 42

100±15 (74%)

Medial Habenula

936± 95

894±94 (4%)

(10-5 M)

(10'5 M)

378± 94 (46%)

197*52 (84%) 1213*121 (4%) -118 *
-16*

9

174 ± 18

5

99 ± 1 8

Nucleus Tractus

636±45 (71%) 2093±137 (4%)

5

457 ± 36
10±

3

238 ± 21
56 ±

8

-9 ± 9

66 ± 1 7

238± 54 (39%)

11 ±

61 ± 12

271 ± 17 (71%)

61 ± 3 6

4

53 ±

7

1 Values in parentheses represent the proportion of specific binding displaced by subtype
selective competition. For some nuclei, total radioligand binding in the presence of both subtype
selective antagonists was less than binding in the presence of unlabelled angiotensin II,
producing negative specific binding values.
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Figure 5-2. Total 125I-SIAII binding (left panels) and adjacent thionin stained sections
(right panels; Bar = 2 mm) a t the nucleus o f the solitary tract (NTS), dorsal motor nucleus o f the
vagus (DMV) and spinal trigeminal tract (SP5).

Figure 5-3. Total 125I-SIAII binding (left panels) and adjacent thionin stained sections (right
panels; Bar = 2 mm) a t the choroid plexus (ChP), nucleus tractus solitarius (NTS) and
posterodorsal tegmental nucleus (PDTg).
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Figure 5-3 illustrates binding in the rostral NTS and the choroid
plexus as it occurs throughout the fourth ventricle. The 125I-SIAII binding in
pontine structures at the level of the genu of the seventh nerve includes diffuse
binding in vestibular nuclei and denser binding associated with the locus
coeruleus (LC) and the posterodorsal tegmental nucleus (PDTg). Binding sites in
the locus coeruleus appear to be a substantial mixture of both ATi and AT2 sites
(Table 5-1).

Midbrain:
The 125I-SIAII binding sites on the medial border of the inferior colliculus
(Figure 5-4) are predominantly AT2. Figure 5-4 also illustrates binding sites in the
parabrachial nucleus and the pedunculopontine tegmental nucleus. Binding in
both nuclei is a mixture of A T t and AT2 sites with A Ti predominating.
The top panel in Figure 5-5 demonstrates binding in the superior colliculus
(SC), periaqueductal grey (PAG), interpeduncular nucleus (IP), the ventral
portion of the caudal hippocampus (VH), and the anterior pituitary. A ^ binding
sites are evident in the posterior segment only of the medial geniculate nucleus
(MG, not illustrated). Diffuse, predominately AT2 binding is evident in the
periaqueductal grey (PAG). Binding is conspicuously absent in the subthalamic
nucleus of the hamster.
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Figure 5-4. Total 125I-SIAII binding (left panels) and adjacent thionin stained
sections (right panels; Bar = 2 mm) at the inferior colliculus (IC), parabrachial
nucleus (PB) and pedunculopontine tegmental nucleus (PPTg).
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Figure 5-5. Total 125I-SIAII binding (left panels) and adjacent thionin stained
sections (right panels; Bar = 2 mm) at the superior colliculus (SC), periaqueductal
grey (PAG), ventral hippocampus (VH), interpeduncular nucleus (IP), pituitary
(Pit), subfornical organ (S FO ) and median preoptic nucleus (MnPO).
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Forebrain
Figure 5-1 shows 12SI-SIAII binding in the hippocampus, medial habenular
nucleus (MHb) and paraventricular nucleus (PV). The dense binding in the MHb
is predominately AT 2 , while the other structures represent mostly ATi binding
sites as described above. Binding is notably absent at the suprachiasmatic
nucleus, medial amygdala and lateral olfactory tract. Figures 5-5 and 5-6
illustrate 125I-SIAII binding in the subfornical organ (SFO), median preoptic
nucleus (MnPO), organum vasculosum of the lamina terminalis (OVLT) and
lateral septum (LS). Binding was also observed in the supraoptic nucleus (not
illustrated). Binding is absent in the piriform cortex while the striatum has diffuse
but conspicuous binding (Figure 5-6).

Hypertensive Hamsters
Table 5-2 describes specific 125I-SIAII binding in the brain nuclei of 4
hypertensive hamsters (systolic, 140-151 mm Hg) and 4 normotensive controls
(systolic, 80-87 mm Hg). There were no significant differences in 125I-SIAII
binding for any of the nuclei studied.

Discussion
The distribution of All receptors in the hamster brain is similar to that
reported in the rat and other species. The similarities are particularly prominent in
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Figure 5-6. Total 125I-SIAII binding (left panels) and adjacent thionin stained
sections (right panels; Bar = 2 mm) at the median preoptic nucleus (MnPO),
organum vasculosum of the lamina terminalis (OVLT) and lateral septum (LS)

nuclei associated with cardiovascular or dipsogenic functions. For example, the
SFO, OVLT, and M nPO have been linked to dipsogenic actions of All, and the
SFO, OVLT, AP, SC, PAG, and NTS have been implicated in the mediation of
pressor responses to All (Speth eta!., 1988). All of these brain nuclei contain
high densities of All receptors in both hamster and rat. Other nuclei involved in
cardiovascular function where dense 125I-SIAII binding is observed in both
species include the PV, M nPO, and DMV. Recent studies have demonstrated
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TABLE 5-2. SPECIFIC 125I-[SA R 1, ILEa]-ANG IOTENSIN II BINDING AT BRAIN
NUCLEI O F NO RM O TENSIVE AND H Y PER TEN SIVE HAMSTER STRAINS.

Nucleus
Pituitary
Subfornical Organ
Median Preoptic n.
Paraventricular n.
Ventral Hippocampus
Nucleus Tractus Solitarius
Spinal Trigeminal n.
Pedunculopontine Tegmental n.
Parabrachial n.
Locus Coeruleus
Inferior Colliculus
Superior Colliculus
Lateral Septum
Medial Geniculate n.
Dorsal Motor n. of the Vagus
Peri-aqueductal Grey
Interpeduncular n.
Choroid Plexus
Medial Habenula
Organum Vasculosum of the
Lamina Terminalis

Normotensive
Hamsters
479 ± 98
860 ± 223
362 ± 71
764 ± 40
353 ± 26
559 ± 53
261 ± 19
304 ± 32
466 ± 31
227 ± 18
271 ± 12
323 ± 36
198 ± 29
213 ±
3
1429 ± 234
159 ± 20
453 ± 35
226 ± 41
503 ± 58
791 ± 112

Hypertensive
Hamsters
603
905
285
819
371
559
263
249
501
217
264
347
210
277
1454
145
528
166
407

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

32
116
20
70
34
53
19
44
48
30
36
55
27
35
158
19
78
32
53

728 ± 120

blood pressure responses to All administered locally at the ventrolateral medulla
(Muratani etal., 1991) of rats. Discemable but weak 125l-SIAIi binding is localized
in this brain region of both the hamster and the rat.
At several nuclei, 125I-SIAII binding was notably different between species.
For example, All receptors have been localized at the inferior olive,
suprachiasmatic nucleus, subthalamic nucleus, medial amygdala, piriform cortex
and various thalamic structures of the rat, but 125I-SIAII binding is conspicuously
absent at these regions of the hamster brain. With the exception of the
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subthalamic nucleus and inferior olive of the human brain (Allen eta!., 1991),
there are no reports of binding in these regions in other species either. There is
particularly dense 125I-SIAII binding in the anterior pituitary of the rat, but
relatively weak binding in the hamster. Binding in the hamster hippocampus is
more extensive than that observed in the rat, and binding in the striatum of the
hamster is more conspicuous than the rat. Binding in the DMV of the hamster is
particularly dense. Intense binding observed in the interpeduncular nucleus and
the medial habenula of the hamster was particularly interesting. All binding is
minimal or absent at these nuclei in the rat brain, and unreported in other species
with the exception of the interpeduncular nucleus of the rabbit (Mendelsohn et
al., 1988) and human (Allen etai., 1991).
The medial habenula and interpeduncular nuclei communicate via the
habenulopeduncular tract (Herrick, 1965; Contestabile and Villani, 1983). This
system has connections to the olfactory and limbic system via several nuclei
which also contain All receptors including: septum (Herkenham and Nauta,
1977), suprachiasmatic nucleus (of the rat) (Sofroniew and Weindl, 1978), locus
coeruleus and dorsal tegmental region (Jones and Moore, 1977), central gray
(Marchand e t a i , 1980), and the ventral tegmental nucleus (Contestabile and
Flumerfelt, 1981). The habenula may be important in linking olfactory sensory
information with motor areas in the brainstem, or in mediating certain emotional
behaviors (Crosby e t a i, 1962; Herrick, 1965; Woodbume, 1967). Lesions of the
medial and lateral habenular nuclei result in the impairment of the ability of rats to
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find food via smell (Rausch and Long, 1971) and furthermore, lesions of the
anterior olfactory nucleus are related to degeneration in the dorsomedial
thalamus and habenula in the opossum (Ferrer, 1969). Perhaps All influences
salt or water seeking behaviors via this system and species variations are related
to differing physiological adaptations to respective natural environments.
The apparent absence of All receptors at the subthalamic nucleus, inferior
olive, piriform cortex, medial amygdala, and suprachiasmatic nucleus in the
hamster, but not in the rat is interesting. These structures process a variety of
sensory information (Paxinos, 1985) and it is difficult to understand how these
two species might function differently in this regard. However, the role of the
suprachiasmatic nucleus in processing photoperiod information to influence
circadian and reproductive cycles (Card and Moore, 1984; Raisman, 1975) is
likely to be different between the species.
Data for losartan and PD 123177 competition at hamster brain nuclei
resembled those observed in rat brain nuclei (Rowe etai., 1992). The percentage
of binding displaced by losartan and PD123177 at each nucleus (Table 1)
approximates the fraction of ATt and AT 2 receptors respectively. This is based
upon assumptions that: 1) the concentration of each competitor is considerably
higher than the IC50 for its higher affinity site and lower than the IC50 for its low
affinity site, 2) AT1 and AT 2 are the only high affinity sites for 125I-SIAII, and
binding kinetics for the radioligand are identical at both sites. These data are not
available for the hamster, but 125I-SIA II shows some selectivity for A Ti receptors
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in the rat brain. However, since the combination of both competitors competed
effectively for all 125I-SIAII binding in the hamster brain, and the sums of
percentage competition for each competitor approximate 100% for most nuclei,
we believe the values for percent inhibition for each competitor in Table 1 closely
reflect the fractional subtype distribution. It is noteworthy that all but two nuclei
show similar patterns of subtype predominance in both the hamster and the rat.
The two exceptions are the medial geniculate nucleus, predominantly ATi in the
hamster and predominantly AT2 in the rat, and the periaqueductal grey that
contains mostly AT2 sites in the hamster and A ^ in the rat. Strikingly, there
seems to be a fraction (approximately 21% ) of specific 125I-SIAII binding sites
uniquely within the dorsal motor nucleus of the vagus that is not displaced by
competition with both losartan and PD123177. Further work will be required to
determine if this is a third receptor subtype, but the existence of binding sites
insensitive to both losartan and P D 123177 has also been reported in Xenopus
laevis oocytes (Ji etai., 1990).
Angiotensin II binding is evident in several hamster brain nuclei associated
with cardiovascular function and several studies indicate disturbances of the
brain angiotensin system in the spontaneously hypertensive rat. Specifically, All
receptor binding is elevated at the subfornical organ, nucleus of the solitary tract,
dorsal motor nucleus of the vagus, locus coeruleus, supraoptic nucleus, and the
organum vasculosum of the lamina terminalis of the SH R (Gehlert etai., 1986b;
Hwang et al., 1986) and we investigated the possibility of similar anomalies in a
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genetic model of hypertensive hamster (Joyner etai., 1988). W e found no
significant 125I-SIAII binding differences in the hypertensive model as compared
to the normotensive control strain at any of the 20 nuclei studied. Thus, the brain
All system does not appear to be implicated in this hamster model of genetic
hypertension.
In summary, 125I-SIAII binding in the hamster brain was localized in
generally the same nuclei as reported for other species, and the receptor subtype
distribution was similar to that in the rat brain. In particular, a predominance of
ATi receptors was observed in nuclei associated with All mediated
cardiovascular and dipsogenic functions in other species. Thus, All mediated
central control of cardiovascular function might be operationally similar in all
mammalian species. In some hamster brain nuclei the presence or absence of
125I-SIAII binding is at variance with observations in other species. This occurs at
nuclei where a role for All has not been investigated and analysis of species
mismatches might provide clues with regard to possible All functions at these
nuclei.
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CHAPTER 6
CHARACTERIZATION O F THE EFFECTS OF CENTRALLY A D M IN ISTER ED
ANGIOTENSIN II ON BRAIN CATECHOLAMINE UTILIZATION

Introduction
Angiotensin and catecholamine systems are known to interact in a number
of ways. Peripherally, angiotensin II stimulates the release of norepinephrine
from adrenal chromaffin cells (Marley and Bunn, 1988.), postganglionic neurons
(Li etai., 1988), sympathetic nerve terminals in the vasculature (Wong etai.,
1992), and brown adipose tissue (Cassis and Dwoskin, 1991). Peripheral
interaction between angiotensin and catecholamine systems reflects functional
commonality between the two systems. Both have potent and profound
cardiovascular actions.
Additionally, angiotensin and catecholamine systems exist within the
brain. Anatomically, a number of brain nuclei appear to belong to both systems.
Angiotensin immunoreactivity and angiotensin II receptors have been co
localized with catecholamine rich cell bodies and/or nerve terminals in the locus
coeruleus, nucleus of the solitary tract, paraventricular nucleus of the
hypothalamus (PV), median preoptic nucleus, intermediolateral cell column and
in the caudal and rostral ventrolateral medulla (Jenkins etai., 1995). Again, the
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commonality of these sites relates to cardiovascular related functions. Peripheral
angiotensin II is known to act at the circumventricular organs to activate
pathways involving the PV, supraoptic nucleus (SON), nucleus of the solitary
tract, and eventually, the rostral and caudal ventrolateral medulla, to influence
autonomic output to the peripheral cardiovascular system (Phillips, 1987;
McKinley etai., 1990).
Central angiotensin II also acts on receptors in the PV and SO N to
stimulate release of the potent vasoconstrictor, arginine vasopressin (AVP) into
the peripheral circulation. Additionally, angiotensin II stimulates drinking through
complex pathways involving the subfornical organ, the anterior wall of the third
ventricle, median preoptic nucleus, and the organum vasculosum of the lamina
terminalis (Johnson and Edwards, 1990; Mangiapane etai., 1983).
Catecholamines have been implicated in both of these responses (Harland etai.,
1989; reviewed in Jenkins etai., 1995). Additionally, All increases
norepinephrine utilization in the anteroventral third ventricle of spontaneously
hypertensive rats (Tsukashima etai., 1996). Sumners and Phillips (1983)
demonstrated changes in norepinephrine and dopamine utilization in the
hypothalamus, striatum and subfornical organ following intracerebroventricular
injection of angiotensin II. Apparently, angiotensin II produces these responses,
at least in part, by modulating catecholamine utilization in these brain regions.
More recently, central angiotensin II has been implicated in the processing
of motor, visual, auditory, olfactory, pain, and thermal information as well as in
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cognition and learning (Barnes e t a i , 1992; reviewed in Wright and Harding,
1994). Three central catecholamine systems have been implicated in learning
and memory: 1) an a-adrenergic system with neurons in the locus coeruleus
projecting through the median forebrain bundle into the limbic forebrain (including
amygdala), hypothalamus and neocortex; 2) a dopaminergic system with
neurons around the interpeduncular nucleus projecting to the substantia nigra
and through the median forebrain bundle to the hypothalamus and
prosencephalon, and projections from the substantia nigra to the striatum; and 3)
a (3-adrenergic inhibitory system in the basolateral amygdala (Gorelick etai.,
1975).
Angiotensin II is known to stimulate synthesis and release of
catecholamines in the striatum and hypothalamus. Approximately 45% of all
noradrenergic neurons in the CNS originate at the locus coeruleus (Swanson,
1976), an area known to contain angiotensin II receptors on noradrenergic
neurcns (Rowe etai., 1990d). Angiotensin II receptors also exist on dopamine
containing cell bodies in the substantia nigra and on their nerve terminals in the
striatum (Jenkins etai., 1995). Angiotensin II receptors also occur in additional
brain nuclei associated with the three catecholaminergic systems described
above (Wright and Harding, 1994). Furthermore, dopamine antagonists block the
cognitive effects of angiotensin II (Hyttel and Christensen, 1983). It seems likely
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that angiotensin II affects memory and learning, and may tend to act in general,
though modulation of catecholaminergic systems.
Interestingly, there is some evidence that catecholaminergic modulation
may be mediated, in part, through AT2 receptors (Xiong and Marshall, 1994).
Confirmation of this finding would dramatically increase our understanding of the
physiological role of AT2 receptors in the brain.
We hypothesize that angiotensin mediates many of its actions through
catecholaminergic systems and that a major portion of the central catecholamine
utilization may be influenced by central angiotensin activity. Furthermore, the AT2
receptor may mediate a portion of this interaction.

Design and Methods
Preliminary experiments were performed to evaluate brain dissection and
intracerebroventricular injection methodologies and dosage and timing for amethyltyrosine pretreatment. The oc-methyltyrosine pretreatment protocol was
chosen based on the effects observed in the preliminary experiments. The
desired effect was a 50% reduction in catecholamine levels. The rationale for this
dosage is that catecholamine levels of 50% of normal is optimal for observing
either increases (resulting in further depletion) or decreases (resulting in less
depletion) in catecholamine utilization. All animals were screened with a drink
test as described in chapter 3. Rats were pretreated with the catecholamine
synthesis inhibitor a-methyltyrosine (200 mg/kg, IP) or saline (IP). Animals
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TABLE 6-1. CO NTRO L AND TR E A TM E N T GROUPS FOR
CHARACTERIZATION O F C ENTRAL A NG IO TENSIN II EFFECTS
ON BRAIN CATECHOLAM INE UTILIZATION.

Pretreatment (IP):

Saline

a-Methyltyrosine
All +

All +

i.c.v. treatment:

aCSF

aC S F

All

Losartan

PD 123177

N:

9

10

10

10

10

treated with a-methyltyrosine were divided into four groups in a balanced design
(table 6-1). Forty-five minutes following pretreatment, animals
received a series of three intracerebroventricular injections as described in
chapter 3 (figure 6-1). Intracerebroventricular injections were given at fifteen
minute intervals and animals were decapitated fifteen minutes after the final
injection. Brains were immediately dissected on ice into left and right cortices,
hindbrain, forebrain and cerebellum. Brain regions were immediately
homogenized and stored at -60°C. Catecholamines (norepinephrine, epinephrine
and dopamine) were extracted and quantitated as described in chapter 3.

rsz;
T=0 min: saline or
a-methyltyrosine
pretreatment (IP)

T=45 min:
I “ I.C.V.
Injection

T=60 min:
2nd I.C.V.
Injection

T=75 min:
3rd I.C.V.
Injection

T=90 min:
Decapitation
and dissection

Figure 6-1. Time line for pretreatment and intracerebroventricular injections.
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The effect of a-methyltyrosine was determined by a Student’s t-test
comparing saline pre-treated aCSF animals with a-methyltyrosine pre-treated
aCSF animals. Differences between a-methyltyrosine treatment groups were
assessed by one-way analysis of variance. Confidence levels of 0.05 and 0.01
were used in determining significance levels in all tests.

Results
Animals surgically prepared for intracerebroventricular injections were
screened for correct cannula placement using a test administration of angiotensin
II (150 picomoles in 3 jil). Animals passing this drinking (table 6-2) test were
randomly assigned to five experimental groups according to table 6-1.
Catecholamine utilization was determined for norepinephrine, epinephrine and

TABLE 6-2. DRINKING (ML) INDUCED BY INTRACEREBROVENTRICULAR
INJECTION O F 150 PICOMOLES O F ANGIOTENSIN II IN 3 \iL
OF ARTIFICIAL CSF, ARRANG ED ACCORDING TO
SU BSEQ U ENT EXPERIM ENTAL GROUPING.
saline
pretreatment
aCSF
16.5
15.2
18.7
14.9
17.1
12.8
17.3
14.3
12.6

aCSF
15.9
10.4
15.8
16.4
13.9
15.4
16.2
12.3
13.9
15.3

a-m ethyltyrosine pretreatment
All
All + Losartan
16.6
11.2
14.9
15.6
13.3
19.0
15.7
15.1
17.4
17.7
13.5
14.1
13.8
18.9
15.8
18.5
11.7
14.0
13.8
13.2

All + PD123177
11.2
17.5
15.0
16.0
14.0
15.2
12.4
13.5
13.7
16.8
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Figure 6-2. Relative norepinephrine content in anim als pretreated with saline (IP) and receiving
i.c.v. injections of aCSF (saline) or a-m ethyltyrosine (IP) and i.c.v. injections of either aCSF,
angiotensin II, angiotensin II + losartan, o r angiotensin II + PD123177. Values fo r the saline group
are 231 (left cortex), 227 (right cortex), 415 (hindbrain), 465 (forebrain), and 138 (cerebellum) ng
norepinephrine per gram tissue. Error bars indicate standard deviations. ** denotes significant
differences (p<0.01) between saline and a-m ethyltyrosine pre-treated animals receiving aCSF by
i.c.v. injection.
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Figure 6-3. Relative dopamine content in anim als pretreated with saline (IP) and receiving i.c.v.
injections of aCSF (saline) or a-m ethyltyrosine (IP) and i.c.v. injections of either aCSF,
angiotensin II, angiotensin II + losartan, o r angiotensin II + PD123177. Values fo r the saline group
are 2044 (left cortex), 1679 (right cortex), 81 (hindbrain), 936 (forebrain), and 58 (cerebellum) ng
dopam ine per gram tissue. Error bars indicate standard deviations. * and ** denote significant
differences (p<0.05 and p<0.01, respectively) between saline and a-methyltyrosine pre-treated
animals receiving aCSF by i.c.v. injection.
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Epinephrine
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Figure 6-4. Relative epinephrine content in animals pretreated with saline (IP) and receiving i.c.v.
injections of aCSF (saline) o r a-methyltyrosine (IP) and i.c.v. injections of either aC SF,
angiotensin II, angiotensin II + losartan, or angiotensin II + PD123177. Values for the saline group
are 5.9 (hindbrain) and 5.5 (forebrain) ng epinephrine per gram tissue. Error bars indicate
standard deviations. * denotes significant differences (p<0.05) between saline and a methyltyrosine pre-treated animals receiving aCSF by i.c.v. injection.

dopamine in the presence and absence of the catecholamine synthesis inhibitor
a-methyltyrosine (figures 6-2 - 6-4). Catecholamine levels are adjusted for wet
tissue weight and expressed as a percentage of saline pretreated levels to
facilitate comparisons. All brain regions demonstrated a highly significant
(p<0.01) decrease (24 ± 3% ) in norepinephrine levels in animals pretreated with
a-methyltyrosine (figure 6-2). Similarly, dopamine levels (figure 6-3) in a methyltyrosine animals were 63 ± 6% of saline pretreated animals (significant in
four of the five brain regions). Epinephrine levels were detectable in only the
hindbrain and forebrain (figure 6-4) and demonstrated a significant
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a*methyltyrosine effect in only the forebrain. Unexpectedly, there were no
significant differences observed between a-methyltyrosine treated animals
receiving intracerebroventricular injections of aCSF, All, or All in addition to
either subtype selective antagonist. This was true for all three catecholamines
observed in all five brain regions.

Discussion
Our methods were sufficiently sensitive to detect 15% changes in
catecholamine content following treatment with a-methyltyrosine. The finding of
no angiotensin II effects implies that despite the extensive anatomical and
functional overlap between the central angiotensinergic and catecholaminergic
systems, the portion of the catecholaminergic system that is influenced by
intracerebroventricularly administered All represents a small fraction of the total
central catecholamine content.
This unexpected finding is difficult to explain considering reports based on
alternative experimental designs employed by other laboratories. Sumners and
Phillips (1983) demonstrated significant alterations in catecholamine utilization in
the hypothalamus and striatum micropunches following intracerebroventricular
angiotensin II administration. These finding have been corroborated by Stadler et
al. (1992) and Mendelsohn etai. (1993). Furthermore, the catecholaminergic
actions of angiotensin II appear to be more pronounced in spontaneously
hypertensive rats (Tsukashima etai., 1996). Recent reports indicate that

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

75

angiotensin II regulates tyrosine hydroxylase gene expression (Yu e ta i., 1996)
and norepinephrine transport system (Lu e t a i, 1996) in neuronal cultures of both
normotensive and spontaneously hypertensive rats.
There is some evidence that angiotensin II modulates the responsiveness
of catecholamine containing neurons to other stimuli. Xiong and Marshall (1990;
1994) have demonstrated that All modulates the response of locus coeruleus
neurons to glutamate excitation via an AT2 receptor mediated pathway. Similarly,
angiotensin II potentiates potassium induced norepinephrine (Qadri e ta i., 1991)
and dopamine (Badoer etai., 1990) release in the hypothalamus. Furthermore, in
the periphery, angiotensin II facilitated adrenal catecholamine release in
response to splanchnic nerve stimulation in hemorrhaged dogs (Kimura etai.,
19S2). However, angiotensin II probably activates catecholaminergic neurons in
a direct manner through a pathway that is synergistic to those of alternative
stimuli.
Nevertheless, even a less direct role for angiotensin II in regulating
catecholamine utilization would fail to completely explain our results. However,
additional angiotensin II activity and/or secondary effects of i.c.v. injection may
have interfered with our measurements. W e occasionally observed slight motor
effects and some catatonia following i.c.v. injections, with subsequent detrimental
effects on drinking responses for All treatment groups. These effects occurred
without regard to treatment group and the few affected animals did not
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demonstrate aberrant characteristics with regard to unaffected drinking
responses. Furthermore, the All treatment group demonstrated no correlation
between catecholamine response and volume drank (NE correlation depicted in
figure 6-5) nor time until onset of drinking (not shown). Therefore, the inclusion or
exclusion of these animals does not significantly alter our findings. However,
these observances indicate the potential existence of similar effects that may be
less observable and more frequent, but that may be equally or more detrimental
with respect to catecholamine responses. These effects probably involve
pathways and brain areas adjacent to the target injection site that are
inconsistently affected depending on the exact cannula placement.
Additionally, we cannot rule out the possibility that angiotensin II acts
directly on catecholaminergic neurons in only a few very discrete anatomical
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Figure 6-5. Correlation of norepinephrine and drinking responses following
intracerebroventricular administration of angiotensin II.
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locations. In our preparation, such responses may be masked by the background
changes in catecholamine content throughout the remainder of the brain. It is
also possible that angiotensin II alters catecholamine utilization differently in
different brain nuclei. The interaction of A T t and AT2 receptors may also differ in
different brain areas.
The experimental design was chosen to obtain a summation (within brain
regions) of potentially small individual catecholamine responses for A T t and AT2
receptors. Our results indicate that the nature of the interaction between the
central angiotensin II and catecholaminergic systems makes this approach
inappropriate. Because we failed to detect a significant angiotensin II effect, the
use of subtype selective antagonists failed to provide additional information.
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CHAPTER 7
SUMMARY, CONCLUSIONS, AND PER SPEC TIVES

Nearly a century has been invested in studying the renin-angiotensin
system. Many rewards are already apparent. Inhibition of the peripheral reninangiotensin system has proven very effective in the management of some forms
of hypertension. The discovery of angiotensin II receptor subtypes and the
availability of selective antagonists will likely provide these benefits with little or
no side effects.
The discovery of a separate angiotensin system in the brain may lead to
additional clinical advances. In addition to cardiovascular regulation, the central
angiotensin system has been implicated in the processing of many types of
sensory information, and in memory and cognition. And we continue to discover
additional functions of this system. These findings suggest that this system may
offer insight into certain dementia including Alzheimer’s disease.
The diverse activity of the angiotensinergic system is possible because of
the diversity of angiotensin receptor subtypes and active peptides. Angiotensin(1-7) and angiotensin IV appear to act through a unique receptor subtypes
(Ambuhl etai., 1994; Swanson etai., 1992) and there are two types of
angiotensin II receptors (ATi and AT2). Further characterization of these
receptors and isolation of the subtypes will allow the many actions of this
78
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system to be studied independently. The utilization of modem tools of molecular
biology are already providing insight into these receptor populations (Nahmias
and Strosberg, 1995) and angiotensin peptides (Lynch and Peach, 1991).
Our research demonstrates the significance of in vitro conditions and
underscores the need to validate in vitro procedures and to be aware of
assumptions implicit in these procedures. W e have validated the binding assay
employed in our laboratory and demonstrated subtype selective effects for some
commonly used buffer constituents. W e also ascertained the degree of
degradation in the absence and presence of individual peptidase inhibitors for
our substituted radioligand. W e then utilized this system in two approaches to
characterize further the functional role of central angiotensin II.
W e compared the anatomical distributions of normal hamsters, genetically
hypertensive hamsters and the previously determined distribution in the rat.
Identification of sites differing in angiotensin II receptor content and subtype
composition (inferior olive, suprachiasmatic nucleus, medial amygdala, piriform
cortex, subthalamic nucleus, anterior pituitary, hippocampus, striatum,
dorsomotor nucleus of the vagus, medial habenula, and the interpeduncular
nucleus) may direct more focused investigations. These differences may
correlate to physiological differences between the two species.
Unlike genetically hypertensive and normotensive rats, hamsters did not
demonstrate elevated levels of angiotensin II receptors in the brains of
hypertensive animals. This finding illustrates the complexity of hypertension
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pathology and indicates that the hamster model may (in some cases) provide an
alternative model to the spontaneously hypertensive rat. The differences
between these models probably relate to different mechanisms of hypertension.
We also investigated the interaction between angiotensin and
catecholamine systems within the brain. Our intent was to demonstrate extensive
general interaction between the two systems and confirm a role for the AT2
receptor subtype in this interaction. Our findings suggest that interactions
between these systems are more complex and less homogenous than we
anticipated. Additional work is necessary to determine the nature of these
interactions.
Even though we were unable to answer all of our questions, we have
uncovered some of the complexity of the central angiotensin system. Now, we
must ‘zoom in’ and isolate specific characteristics for more direct examination.
The species differences in receptor binding include many brain nuclei at which
the function of angiotensin II is not presently known. Additional work may
associate these differences with known physiological differences between the
animal models. Much work needs to be done to examine the potential
neuromodulatory role for angiotensin II in catecholaminergic systems. The exact
role each of these systems and their interaction in memory formation and
cognition remains to be determined. Perseverance and continuing advances in
technology will eventually resolve these challenges.
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